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T
his year’s World Health Summit found us face-to-
face with a challenge of unprecedented scale: For 
the first time ever, more than 60 million people are 
fleeing war, terror and persecution. The effects have been 
profound. Europe, seen for decades as a model of cooper-
ation and friendship, is diverging from its blueprint. 
Social norms and contracts are dissolving under the 
weight of mistrust and short-term interests. In many 
countries, health systems are struggling hard with the 
duty of providing care for those in need. 
Experience shows that there is only one way to confront 
these paramount issues: We have to build up trust again 
and intensify international cooperation. Last year’s G7 
summit emphasized these issues and the German govern-
ment ties its G20 Presidency at the end of 2016 to sharp-
ening this focus and working on reforming the global 
healthcare structure, as Chancellor Angela Merkel ex-
presses in her Welcome Message. This strong political will 
is in alignment with the internationally endorsed Sustain-
able Development Goals (SDG) and highly promising 
developments in translational research that cross the 
boundaries between science and medicine, as well as the 
increasing accessibility of data and powerful new tools.
This spirit of cooperation permeated the WHS Geneva 
Meeting in April 2016, held on the occasion of the 
Geneva Health Forum’s (GHF) sixth edition and 10 year 
anniversary. It emphasized the continuous commitment 
of the Swiss government and the GHF organizers to glob-
al health and peace, thus providing a sterling example of 
partnership and friendship while sounding a clear call for 
collaboration across all health-related sectors. 
To continue this call, the World Health Summit 2016 
drew more international experts from academia, politics, 
the private sector and civil society than ever before. Their 
deliberations focused on topics including:
 ȣ Migration and Refugee Health:  
From Care to Policy
 ȣ Technological Innovation for Health:  
Improving Healthcare Delivery
 ȣ Women, Empowerment and Health:  
Equality and Agency
 ȣ Translational Research:  
Advancing Innovative Treatment
 ȣ Infectious Diseases:  
Lessons Learned from Ebola to Zika
 ȣ Sustainable Development Goals:  
Transforming the Health Agenda
Supported by the M8 Alliance of Academic Health Cen-
ters, Universities, and National Academies, this meeting 
demonstrates how trust and cooperation can improve 
lives worldwide.
What better goal could we collectively target than the ob-
jective of longer, healthier lives that can be lived out in 
peace? Please join us as we work toward this goal.
Editorial
PROF. DR. ANTOINE FLAHAULT
WHS President
PROF. DR. DETLEV GANTEN
WHS President
WHS GENEVA MEETING 2016
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Welcome Messages
T
he individual desire for health and well-being is 
something we all share. With this in mind, one of 
the aims of the 2030 Agenda for Sustainable Devel-
opment is to encourage people across the globe to live 
lives that are as healthy as possible at every stage of their 
existence. We committed ourselves to this goal last year 
within the framework of the United Nations. Now we 
have to implement this ambitious objective. That involves 
fighting epidemics and poverty-related diseases and also 
extends to improving prevention and treatment of com-
plaints of modern civilization such as diabetes and car-
diovascular disorders.
Germany plays a very active role in global health 
policy. To bring about further progress, we must strength-
en healthcare systems worldwide and reform the global 
healthcare structure. We sharpened the focus on both 
these issues during Germany’s G7 Presidency. We intend 
to build on this when our country assumes the G20 Pres-
idency at the end of this year. 
Whether we are talking about institutional factors 
or other global health issues such as a joint approach to 
tackling antimicrobial resistance, we can only be effective 
in overcoming the challenges they present if scientists, 
policymakers and society work together side by side. This 
is why dialogue forums such as the World Health Summit 
are particularly important. As the patron of the Summit, 
I would like to welcome all participants to Berlin. This 
message comes with my hope that you will enjoy a fruitful 
exchange of new insights. I would like to thank you most 
sincerely for your remarkable commitment to advancing 
healthcare throughout the world.
T
he themes discussed during this eighth World 
Health Summit are both ambitious and strategic. 
They also reflect the deep changes we are seeing in 
the world. The terms of globality and universality are 
now, more than ever, associated with health: quality care 
for all, accessible to all; international preventive mea-
sures; renewed support for health as a driver of develop-
ment, growth and stability; and an ambitious research 
policy, which is a source of progress. These are principles 
to which France is committed, and which it supports in 
international bodies. France thus obtained, during the 
last G7, that reflection will take place at the international 
level on access to expensive medicines. This Summit is a 
forum for discussion and dialogue, bringing together 
men and women of “good will.” That means it is a place 
of peace.
I wish you all excellent meetings.
DR. ANGELA MERKEL
Chancellor of the Federal Republic of Germany
FRANÇOIS HOLLANDE
President of the French Republic
EUROPEAN UNION
The place to be for life sciences 
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t is impossible to talk about health issues in the past 
year in Europe without reflecting on the refugee crisis, 
and the challenges and opportunities that it has pre-
sented for Europe. Over one million children, women 
and men arrived at our shores and borders last year.
The European Union had a common responsibility 
to ensure that these persons, many of them physically and 
mentally exhausted, were offered care and support, 
including through the provision of healthcare when 
required. Their journeys were punishing, and we cannot 
imagine the impossible choice they had to make between 
staying in their countries in extreme danger and the 
unenviable alternative of risking their lives at the hands of 
people smugglers. Europe’s number one task was to offer 
these people a humane reception in Europe, which the 
Commission helped to achieve by the setting up of 
hotspots in Greece and Italy, and through financial and 
practical assistance to our Member States under our 
emergency asylum funding and through the EU’s Civil 
Protection Mechanism. 
Our next priority is to ensure the effective integra-
tion of those that are granted international protection. 
For some, that will mean gaining access to our health ser-
vices. At the same time, the people who arrive in Europe 
must be given the opportunity to pay their way, through 
access to the labor market. And there is an obvious coun-
terbalance to the demands they make of our healthcare 
system with the contributions that they can make to it. I 
hear of many medical professionals coming to Europe 
seeking to rebuild their lives; doctors and nurses, phar-
macists and researchers, carers and therapists. In the next 
year I hope to hear heartwarming stories of their integra-
tion into our national health services, care homes, 
research institutes and universities, and the valuable 
contribution they are making.
And one reason to welcome these new arrivals is 
the reason I gave you in my message for last year’s World 
Health Summit – Europe’s population is getting older, 
which makes it increasingly difficult to provide for our 
healthcare needs. I know that you will again address the 
JEAN-CLAUDE JUNCKER
President of the European Commission
healthcare challenges of an aging population at this year’s 
Summit. Setting strategic research priorities will be of 
fundamental importance, and I am pleased that the Euro-
pean Commission continues to make an important con-
tribution through our Horizon 2020 funding program.
Another area where we are making an important 
contribution is eHealth. More and more people are taking 
steps to monitor their own health and lifestyles through 
wearable devices and smartphones. These form an excel-
lent contribution to preventing and monitoring diseases. 
Through the Connecting Europe Facility, we are contrib-
uting to building Europe’s digital health infrastructure. So 
far, 20 of our Member States have applied for funding to 
connect their systems and exchange health data and 
patient information or to offer e-prescriptions and reduce 
the administrative burden on our care systems.
Let me conclude by mentioning the healthcare 
industry, which is one of the major drivers of jobs, growth 
and innovation in Europe. We need a successful economy 
to sustain our European social model, and you are an 
intrinsic part of this with the many thousands of jobs you 
create and sustain. The world is getting older, and the 
world is in need of health technology to sustain us as we 
go through a major demographic change. Europe must 
lead the way in looking after its own citizens, and it must 
generate a competitive advantage in the global market for 
healthcare services and products.
I wish you a fruitful Summit, and another year of success.
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World Health Summit – Mission and Goals
T
he World Health Summit 
(WHS) is one of the world’s 
most prominent strategic fo-
rums for global health. The interdis-
ciplinary, international event takes 
place within an atmosphere of aca-
demic freedom.
Every October, internationally re-
nowned leaders and representatives 
from the sciences, politics, business, 
and civil society travel to Berlin for 
the WHS to discuss the latest chal-
lenges facing medical research and 
healthcare. Under the high patron-
age of German Chancellor Angela 
Merkel, French President François 
Hollande and European Commis-
sion President Jean-Claude Juncker, 
the World Health Summit is the pre-
miere international platform for ex-
ploring strategic developments and 
decisions in the area of healthcare. 
The World Health Summit’s academic 
think tank is provided by the “M8 
Alliance,” a unique collaborative net-
work made up of leading interna 
tional medical universities, research 
institutions and the InterAcademy 
Partnership (IAP) for Health – repre-
senting science academies worldwide. 
The M8 Alliance selects the World 
Health Summit’s rotating annual 
president and also organizes the asso-
ciated Regional Meeting that takes 
place each April. 
Under the leadership of Charité – 
Universitätsmedizin Berlin, the medi-
cal alliance was set up in 2009 along 
the lines of the G8 political forum. 
Today, it is made up of 24 members 
from 17 countries.
THE THREE PILLARS OF THE 
WORLD HEALTH SUMMIT
• Global challenges: At the WHS, 
participants discuss and debate 
topics such as chronic disease, the 
application of modern technolo-
gies in the healthcare sector, vacci-
nation and immunization, the 
promotion of innovation and 
interdisciplinary cooperation in 
healthcare research.
• Global responsibilities: Advances 
in medicine have to reach people 
faster and more effectively. 
Sustainable approaches must play 
a central role in this process, and 
the means for doing so are a major 
focus at the Summit. 
• Global networking: International 
figures and bodies from the fields 
of science, politics, business and 
civil society come together to 





An International Forum for
Networking, Exchange and
Policy-Shaping Debate
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PROF. DR. STEVE WESSELINGH
WHS President 2011 | Australia 
“It was a great honor to jointly 
preside over the 2011 event, as it 
demonstrated for the first time 
the truly global reach of the 
WHS, with significant involve-
ment from the Asia-Pacific 
region. There was clear evidence 
of the potential of the Summit to 
facilitate positive change on a 
genuinely worldwide scale. It 
highlighted new approaches in 
research and innovation dealing 
with a complex mix of escalating 
rates of non-communicable 
diseases, climate change and 
worldwide political instability.”
“The recognition that academic 
health science centers needed 
to be engaged in the global 
health debate was a central 
lesson. Good debates addressed 
the promise of precision 
medicine requiring even closer 
collaboration between academ-
ic institutions, healthcare 
providers and social and 
community care, as well as the 
need to use developments in 
digital health and data 
analytics to provide real-time 
healthcare choices at both the 
personal and public health 
levels.”
PROF. DR. STEPHEN K. SMITH
WHS President 2010 | United Kingdom
“The highlight of the 
WHS’s first edition was 
the concept of evolution-
ary health and how it 
linked global health and 
the Darwinian principles 
of evolution. One of my 
most cherished memories 
until today is the live 
discussion we had with 
the crew of the interna-
tional space station.”
PROF. DR. AXEL KAHN
WHS President 2009 | France
Past WHS  
Presidents reflect 
on a legacy  
of engagement
World Health Summit – Mission and Goals
“The WHS 2013 showed that there 
is a need for leading academics, 
policymakers, and shapers of civil 
society to collectively develop 
strategies to address important 
health issues which affect our 
society. Following our Regional 
Meeting in Singapore, we were able 
to make significant progress in 
helping the region with issues 
ranging from uni versal health 
coverage implemen tation to 
medical education and research 
collaboration.”
PROF. DR. JOHN EU LI WONG
WHS President 2013 | Singapore
“We wanted to grow the number 
and breadth of stakeholders 
attending that meeting – which 
definitely happened. At the same 
time, we aimed at increasing the 
number of universities that are 
members of the M8 Alliance, 
which happened with great 
success as well. It includes now 
universities from around the 
world and still more will be 
joining in the future. Personally,  
I made great connections with 
colleagues and investigators 
from around the world through 
this network. Some even grew 
into lasting friendships.”
PROF. DR. MICHAEL J. KLAG
WHS President 2012 | USA
“The WHS 2014 contributed to 
improving health on a global scale 
by providing approaches which 
combined classic public health 
rules with new strategies, some 
setting explicit goals to integrate 
public health with general welfare 
policy. Health for all, health 
promotion, and population health 
contribute to this reorientation in 
thinking and strategy.”
PROF. DR. JOSÉ OTÁVIO  
COSTA AULER JÚNIOR
WHS President 2014 | Brazil
“The recognition that 
academic health 
science centers needed 
to be engaged in the 
global health debate 
was a central lesson. 
Good debates ad-
dressed the promise of 
precision medicine 




and social and 
community care, as 
well as the need to use 
developments in digital 
health and data 
analytics to provide 
real-time healthcare 
choices at both the 
personal and public 
health levels.”
PROF. DR. SHUNICHI FUKUHARA
WHS President 2015 | Japan
World Health Summit - Mission and Goals
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The M8 Alliance currently has 24 
members based in 17 different 
countries, each of which are 
committed to improving global 
health and working with political 
and economic decision-makers to 
develop science-based solutions to 
health challenges worldwide.
The M8 Alliance promotes the 
bench-to-bedside-to-population 
health translation of research, as 
well as the transformation of 
current medical care approaches to 
treating the ill by creating health-
care systems aimed at the effective 
prevention of disease. The organi-
zation also works to adapt 
health-related solutions to rapidly 
changing living conditions through 
research in priority areas, in 
particular shifting demographics, 
urbanization and climate change.
The M8 Alliance is improving global 
health through the pursuit of five 
strategic goals:
• developing a worldwide network 
of academic health science centers 
and bringing together universities 
and healthcare providers;
• facilitating dialogue through the 
World Health Summit across a 
global network of stakeholders 
who are engaged with academic 
health science centers – these 
stakeholders include individuals 
and institutions active in govern-
ment, industry and commerce, 
inter-governmental agencies, 
healthcare providers, academies of 
medicine and science, professional 
associations, and the media;
• setting an agenda for global health 
improvement by addressing issues 
of interest to academic health 
science centers and conveying 
findings and recommendations 
based on scientific evidence 
through the generation of key 
statements;
• positioning the M8 Alliance as an 
authoritative influence when it 
comes to decision-making in 
global health; 
• creating a knowledge base amongst 
M8 Alliance members, which 
directly involves the promotion of 
mutual learning, research collabora-
tion, the enrichment of educational 









The M8 Alliance of Academic Health Centers,  Universities 
and National Academies is a collaborative network of 
 academic institutions known for its educational and research 
excellence. The network was founded in 2009 at the 
 inaugural World Health Summit, and has provided an 
 outstanding academic foundation to every WHS event since.
M8 Alliance
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University of São Paulo, Brazil
Founded in 1934, the University of 
São Paulo arose from a combination 
of institutions, including a medical 
school. Today, the largest university 
in Brazil is seen as the country’s 
most prestigious edu cational 
institution.
IAP for Health
The IAP for Health combines the 
expertise and impact of the global 
network of science academies to 
advance sound policies, promote 
excellence in science education and 
improve public and global health.
World Federation  
of Academic Institutions for 
Global Health (WFAIGH)
A global network of academic 
health institutions, the WFAIGH was 
set up to help provide evidence  
to inform policies on global health 
issues.
Association of Academic 
Health Centers Intenational 
(AAHCI)
The AAHCI is a global non-profit 
organization that aligns efforts 
among health professionals in edu - 
cation, research and patient care.
Chinese Academy of Medical 
Sciences & Peking Union 
Medical College, China
The college is among the most 
selective medical institutions  
in the People’s Republic of China 
and one of its top two universities. 
Russian Academy of Medical 
Sciences, Russian Federation
Set up in 1944, the USSR Academy 
of Medical Sciences was considered 
the most prestigious scientific and 
medical organization in the Soviet 
Union. Its successor – the Russian 
Academy of Medical Sciences –  
was founded in 1992.
University Sorbonne  
Paris Cité, France
The University Sorbonne Paris Cité 
is a recently established consortium 
of prestigious institutions that brings 
together higher education and 
research institutions in the city of 
Paris. 
University of Geneva,  
Switzerland
Founded in 1559 as a theological 
and humanist seminary, the 
University of Geneva is renowned 
for emphasizing the unity of 
teaching and research. It’s the  
only tertiary-level educational 
institution of its kind in the region.
Geneva University Hospitals, 
Switzerland
The Geneva University Hospitals  
are heirs to a centuries-long 
tradition of excellence in medicine 
and science. The HUG represents  
a merger all public hospitals in 
Geneva.
Graduate Institute Geneva, 
Switzerland
A semi-private post-graduate 
institution, the Graduate Institute 
Geneva was the first university in 
the world to be dedicated solely  
to the study of international affairs.
University of Montreal, Canada 
A public research university that 
started with less than 100 students 
in 1878, the University of Montreal 
has more than 60,000 today. 
Comprised of 13 faculties and more 
than 60 departments, it has the 
highest sponsored research income 
in Quebec.
Montreal Clinical Research 
Institute, Canada
The IRCM was the first independent 
academic research center in Quebec 
to bring basic and clinical researchers 
together under a single roof.
M8 Alliance
 
Makerere University,  
Uganda
One of the oldest and most  
pres tigious centers of learning  
in Africa, Makerere University  
is home to a staff of over 4,000  
and more than 40,000 students.
Monash University, Australia
As Australia’s largest university –  
with approximately 60,000 
students from over 170 countries – 
Monash has seven campuses:  
five in Victoria, one in Malaysia  
and another in South Africa.
National University  
of Singapore
Founded in 1905, the National Uni - 
versity of Singapore today consists 
of 16 different faculties and schools. 
Around 37,000 students can be 
found on its three campuses in 
Singapore and seven overseas 
locations.
National Taiwan University, 
Taiwan 
Known for its diverse and interna-
tional curriculum, National Taiwan 
University is made up of 11 colleges, 
54 departments and 105 graduate 
institutes. It has a student body of 
around 30,000.
Sapienza University  
of Rome, Italy 
Established in 1303 by Pope Boniface 
VIII, Sapienza is one of the oldest 
universities in the world. With about 
115,000 students, it’s one of the 
largest in Europe as well.
Tehran University of Medical 
Sciences, Iran
The university is the oldest, largest 
and most highly ranked comprehen-
sive higher education institute in  
the field of medicine and public health 
in Iran, offering a wide range of 
courses and receiving applications 
from students from around the globe.
Charité – Universitätsmedizin 
Berlin, Germany
Europe’s largest university clinic – 
and its oldest and most prominent 
hospital – is located in the German 
capital. Eleven Nobel Prize laureates 
have worked at the Charité.
Coimbra Health, Portugal
Over 700 years old, the University 
of Coimbra is a keystone of Europe-
an and global scientific culture, as 
well as a UNESCO World Heritage 
Site. Together with the Coimbra 
Hospital and University Center,  
it forms Coimbra Health. 
Imperial College London, UK
The Imperial College of Science  
and Technology was created as a 
constituent college of the University 
of London. Fully independent since 
2007, the Imperial College London 
attracts students from more than 
100 countries.
London School of Hygiene &  
Tropical Medicine, UK
Founded in 1899, the London 
School of Hygiene & Tropical 
Medicine is one of the leading 
research-focused graduate schools 
in the world.
Johns Hopkins Bloomberg 
School of Public Health, USA
A fully accredited private institution, 
the JHSPH was the first public 
health facility in the world, and it 
remains the largest school in the 
field.
Kyoto University Graduate 
School of Medicine, Japan
The first institution of its kind in 
Japan, the Kyoto Imperial Uni-
versity College of Medicine was 
founded in 1899. Its successor, the 
Kyoto University School of Public 
Health, was established in 2000. 
M8 Alliance
Migration and  
Refugee Health
According to the United Nations, there are an 
estimated 65 million forcibly displaced people 
worldwide, including 21 million refugees. The  
statistics can be overwhelming – and numbing.
“The numbers hide one thing,” International 
Committee of the Red Cross Director Yves  
Daccord said in a speech at the WHS. “Behind 
every number there is a person. When it  
comes to migration and health, you need to  
understand the person.”
Caring for the many people displaced by war,  
famine or natural disaster is a challenge that  
requires medical professionals to think outside  
the box. To be effective requires an understanding 
of different cultural backgrounds, the political  
and social roots of conflict, and the isolation and 
despair that threaten refugees’ mental health.
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Migration and Refugee Health
I. FEARING THE FOREIGN
Across the globe, migration and its impact on individual, 
family, and population health have emerged as a societal 
challenge. Whether concerns around migration and 
refugees are anchored in the perception of migrants 
bringing with them communicable diseases or migrants 
taking away limited resources from local populations, 
they share in common undifferentiated scapegoat 
narratives that should have no place in the multicultural 
societies of our time.
Although a “fear of the foreign” is, perhaps, as ancient as 
the concept of “self and other,” today our moral and ethi-
cal obligation to assist those who come to us (both in 
existential need as in the spirit of improving their lives) is 
accompanied by an unprecedented experience of global 
citizenship. If we are indeed one world, we need better 
ways of addressing how and why others become vulnera-
ble. Otherwise, the flowing wave of human migration will 
increasingly become a storm.
But while policymakers in receiving countries focus on 
quotas and points-based systems, on procedures for 
accepting or refusing migrant and refugee claims, and on 
migration’s impact on economic growth, individual views 
and community responses to migrant and refugee needs 
are complex. In the end, the ability of any person to thrive 
in a new home will also depend on the willingness of 
communities in receiving states to accommodate others 
whose lifestyles may diverge from local ways of living. 
Crucially, this ability rests on understanding and success-
fully addressing the needs that stem from the unsettling 
of individuals and communities in the first place. And it 
rests in the longer term on how migrants and their fami-
lies adjust and develop the social networks that are cen-
tral to living lives fully realized. This last contingency is 
why it is important to distinguish between migrant health 
and the health of forced migrants, including refugees.
II. MIGRATION AND FORCED MIGRATION
Migrants are people who move from their places of origin 
and settle elsewhere. That in itself can be challenging and 
complex. Many of the world’s megacities are already made 
up mostly of such people. But refugees are stateless people 
whose civil liberties can remain unacknowledged or open-
ly denied, leaving them both vulnerable to changing na-
tional sentiment and deeply dependent on humanitarian 
goodwill. 
To address refugee health requires, then, a careful assess-
ment of their specific vulnerabilities and a sustained com-
mitment to ameliorate what has made them vulnerable. 
However, given the real tragedies that make people seek 
refuge, that commitment must be honest and enduring. 
This is why refugee health is so profoundly dependent on 
social trust and on the reliability and wisdom of political 
leaders. As important as is individual conviction, if 
governments fail to act in openly humanitarian ways, citi-
zens are asked to be generous without the assurance that 
their generosity will be either acknowledged or supported. 
This fact has been known for a long time. Indeed, John 
Maynard Keynes long ago referred to that failure of 
governments to express generosity in moments of social 
stress as the “paradox of thrift.” The “paradox” for Keynes 
rested in the destabilization created when leaders, citing 
resource limitations, cut back on social welfare exactly at 
the time when citizens needed to believe that their 
governments will be there for them no matter what. 
According to Keynes, the corrosive effects on public trust 
under such conditions are immeasurable. 
III. POLITICAL WISDOM
But wisdom is a precious commodity. And when it is ab-
sent, addressing migrant and refugee health and well- 
being can become problematic; for so many people are 
unsure whether to look right or left in an effort to build a 
healthier and more vibrant society. We hear from the po-
litical right that the house is filling quickly and must be 
ring-fenced from those who may exhaust its resources if 
we are to care responsibly for citizen health and welfare. 
From the left we hear that the house itself may need re-
building, and that the only morally acceptable way of re-
plenishing those cupboards is by opening the front door.
But the truth is that public sentiment is never so clear-
cut. Were the choice that simple, receiving countries 
would with one voice either accept or reject outsiders; 
and that is not at all what we now witness. Rather, a 
straightforward political divide is mediated by a deeper 
and much broader public mistrust of government. When 
leaders retreat from the frontline of the policies that they 
once supported and openly fought for, public trust col-
lapses and with it the health of migrants and refugees is 
jeopardized. 
When public anxiety is present, it is little wonder that 
anti-migration sentiment becomes a primary way in 
which people both voice mistrust in political processes 
and claim that society can hardly be expected to care for 
others. Migrant and refugee needs, in other words, tell 
us a great deal more about citizen trust than we often 
acknowledge. So immigrant health has to be placed 
against the background of wide-scale public anxiety, if 
we are to understand the long-term impact of our 
political decisions. 
This is why those who already feel disenfranchised and 
disillusioned by political processes are often most vocally 
against that nation being generous, even to the point of 
supporting policies that may not be in the best interest of 
citizens themselves. One merely has to follow the irre-
sponsible chaos created across Europe by Brexit, or the 
radical political shifts on migration in the United States, 
Australia and elsewhere to understand how migrant 
health and migrant well-being are entangled with politics. 
Caring for the health of migrants and refugees is not only 
about available resources or even about cultural competency.  
It is also about political wisdom and social trust. 
MIGRATION AND 
REFUGEE HEALTH
IV. THE NEW CONVERSATION
Migration has forced new conversations about human-
kind and its values, and the health outcomes of all of us 
will be determined by how we adjust globally to the real-
ity of a world in which actions in one country will have 
significant impacts in other places. 
But it is here, also, where we have a real opportunity. Like 
climate change, migration demands new forms of coop-
eration – at the individual level, in communities, within 
nations, and across national borders. This truth means 
that migration is not a thing to be resolved by any one 
country’s attempt to close itself off to the realities of 
global disorder and the dire human needs of so many 
stateless peoples worldwide.
In other words, we all need to ask ourselves why someone 
would migrate in the first place, and to commit collective-
ly to addressing this much bigger question. That means 
understanding the root causes of migration, for no walls 
or fences will stop the flow of people around the globe 
when migration is driven by an urgent desire to find the 
social security we all so much hope for.  
OVERVIEW
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hat keeps you up at night?” is a popular ques-
tion directed at security leaders and 
decision-makers. Often, their responses refer 
to weapons of mass destruction (WMD), the use of which 
could kill people on a massive scale. Answers usually have 
an atomic component, ranging from the risk of nuclear 
terrorism to a catastrophic escalation of conflict between 
nuclear weapons powers. Bioterrorism, especially after 
the 2001 anthrax scare in the United States, is also near 
the top of the list – although it is not certain we are actu-
ally prepared for such an attack. But, many will admit, an 
epidemic stemming from natural causes has long not 
received the attention it deserves. Yet an epidemic could 
also bring about mass destruction – but there would be 
no enemy to blame but ourselves for not being prepared.
“Freedom is indivisible, and when one man is enslaved, 
all are not free,” US President John F. Kennedy famously 
said in his “Ich bin ein Berliner” speech. Paraphrasing 
him, one might also say: When one human is sick, all of 
us may be threatened. Unfortunately, it did take a major 
outbreak of a deadly disease, the Ebola crisis, to high-
light that danger again: The health systems in place in 
one country can have a great impact on global health as 
well as on international security and stability. Without a 
doubt, “the unprecedented extent of the Ebola outbreak 
in Africa constitute[d] a threat to international peace 
and security,” as the UN Security Council found in Sep-
tember 2014.
One the one hand, none of this is new. Since the plague 
killed almost 1 in 3 Europeans in the 14th century, states 
have recognized that diseases can pose a disastrous dan-
ger and have tried to take necessary precautions. And in 
the 20th century, in particular, there have been important 
health success stories, including the advent of antibiotics 
and the eradication of small pox. 
KEY GLOBAL TRENDS INCREASE THE RISK OF 
PANDEMICS
On the other hand, key global trends and characteristics 
of today’s international system create a higher risk of a 
catastrophic global pandemic. 
First, the progression of globalization, urbanization and 
population growth keeps decreasing the time between the 
outbreak of a disease and its spread. These trends are not 
entirely new, but they are accelerating – and make it more 
difficult to get a pandemic under control again. In other 
words, the 2002-2003 severe acute respiratory syndrome 
(SARS) pandemic may only be a light blueprint of how a 
much deadlier global spread might occur. For example, 
Africa’s population is projected to more than double by 
2050, and most of that growth will be in cities. Population 
density in megacities can speed up the spread of diseases – 
and make widespread unrest and chaos more likely in 
case of an outbreak. 
Second, the proliferation of state failure throughout 
key parts of Africa and the Middle East is also accelerat-
ing, which exacerbates health security challenges in those 
countries. After all, preventing or responding to disease 
outbreaks is extremely difficult in areas with limited gov-
ernance or in areas of civil strife and war.  
And consider this: We all know that if Ebola had been an 
airborne pathogen of a similar lethality, the outbreak 
could have caused millions of deaths. But, under different 
circumstances, Ebola could have been just as cata- 
strophic: What would have happened if, for instance, 
populous Nigeria had been in complete turmoil in 2014 
– or did not have relatively good health infrastructure in 
place from the fight against polio? If Ebola had spread to 
the megacity of Lagos under conditions of a civil war in 
Nigeria, the world would be very, very different today.
Moreover, the proliferation of state failure and civil con-
flict in today’s world has also led to the biggest refugee 
crisis in history, leaving many millions of migrants vul-
nerable and without adequate healthcare. And these state 
failures, by the way, also increase the risk of terrorist 
groups having safe spaces to flourish and possibly even 
plot attacks with weapons of mass destruction, including 
biological weapons.
Conversely, of course, health security crises feed and fos-
ter instability as well; the Western African states most af-
flicted by Ebola will need years and years to fully recover. 
In some countries, HIV/AIDS has decimated entire gen-
erations. Beyond the millions of personal tragedies, the 
societal, economic and political consequences of such a 
massive health challenge can hardly be exaggerated. 
Add to this challenge antimicrobial resistance, which ex-
perts say will skyrocket in the next decades and thus 
make treatment of common infections and bioterrorism 
more difficult, and you get a worrisome picture.
These are a few critical issues at the intersection of health, 
security and stability – and I have not even mentioned the 
protection of healthcare workers in conflict zones or the 
role of militaries in fighting outbreaks yet. 
These are also some of the key reasons why I have been 
committed to promoting discussions between health offi-
cials, NGOs, security strategists, the private sector and 
decision-makers at Munich Security Conference events 
in order to deepen the conversation between profession-
als from different sectors.
To be sure, none of this is to suggest that security officials 
should only care about health questions if and when they 
have an impact on security policy in the traditional sense. 
It is true that health policy and security policy are two 
different policy areas, with sometimes competing priori-
ties. Mixing them all together and “securitizing” health as 
a matter of principle is not sensible. But it would also be 
negligent to downplay the critical intersection of the two. 
A comprehensive understanding of security today must 
include health security.
In addition, in terms of communication, it might be use-
ful to frame global health emergency preparedness in se-
curity terms. This could help sharpen the awareness 
among publics around the world that this is not just a 
problem of and for certain regions, and certainly not just 
for less developed countries, but that this problem affects 
everyone. It could help find the funds necessary for re-
search and development, for disease surveillance, and for 
health and response systems. The launch and first opera-
tion of the European Medical Corps in the Congo, for 
example, has been a good step.
Moreover, it would be useful to routinely and promi- 
nently include health in security strategies, risk assess-
ments and early warning mechanisms. Health systems 
are, after all, a line of defense. They help prevent both 
health and security crises, and thus strengthen our 
common security.
Speaking at a panel discussion on the intersection of 
health and security policy at this year’s Munich Security 
Conference, Ghana’s Minister of Foreign Affairs and Re-
gional Integration, Hanna Serwaah Tetteh, observed: 
“Even though the discussion [of health security] is now 
more prevalent within our region and within our conti-
nent, […] I’m really wondering whether the lessons have 
been learned as well globally as they have within the place 
where we suffered the crisis.” 
Global health and global security may well depend on 
learning those lessons without further delay.  
Health, security and stability are inextricably linked.  
As global instability and interconnectedness increase, so does 
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ur species, Homo sapiens, originated in Africa. 
Between 60,000 and 70,000 years ago, we started 
to migrate to other continents, probably due to a 
major climate change which almost caused the species’ 
extinction. To date, we continue to migrate and mix. The 
result is that, after centuries of racism and discrimination, 
scientists – and many others, though unfortunately not 
everyone – realize that human “races” do not exist. In other 
words, there are no exclusive genetic characteristics corre-
sponding to black people, white people, etc.
The phenomenon of migration is also part of the Europe-
an Union’s DNA. In the aftermath of World War II, the 
fathers of the EU proposed the creation of the European 
Coal and Steel Community (ECSC). One of its motiva-
tions was to make another “war not merely unthinkable, 
but materially impossible.” The ECSC made possible the 
migration of workers – including around 140,000 Italians 
who moved to Belgium between 1947 and 1957 – who 
accepted very hard working conditions to try to improve 
their socioeconomic status.
MIGRATION STRESSORS AND MENTAL HEALTH 
OF REFUGEES
According to the United Nations High Commissioner for 
Refugees (UNHCR), there are currently about 65 million 
forcibly displaced people worldwide, including about 21 
million refugees (over half of whom are under the age of 
18) and 10 million stateless people. The vast majority of 
these forced migrations are towards low and middle-in-
come countries and “only” about 1.2 million towards the 
EU. But the impact has nonetheless been dramatic.
Several studies indicate that refugees have higher morbid-
ity from several mental health disorders such as post-trau-
matic stress disorder, anxiety and depression compared to 
the native population or family reunification immigrants. 
That could be due to different type of stressors: 
Pre-migration stressors
Many of the refugees reaching the EU from Middle Eastern 
and sub-Saharan countries have fled due to wars, persecu-
tion and extreme violences, such as torture, loss or murder 
of family members and friends, and rape. 
High-income countries should make a stronger commit-
ment to prevent any type of conflict in the world and 
induce non-democratic countries to respect human rights. 
This may, at first, appear to be a naïve and idealistic state-
ment but instead it is a very concrete one. Besides the 
obvious ethical reasons, prevention of wars, poverty, hun-
ger, etc. would drastically reduce forced migrations and 
ultimately be less expensive to deal with than the conse-
quences of these tragedies. Higher investments in coopera-
tion for development to stabilize areas at risk would save 
hundreds of thousands of lives and reduce the suffering of 
millions of human beings. Just as in medical practice, 
prevention is much cheaper and effective than therapy.  
During migration stressors
Refugees reaching the EU have often traveled for weeks, 
months or even years. Most of them crossed the Mediter-
ranean Sea, sometimes losing family members and 
friends along the way (3,771 people drowned or went 
missing in 2015 alone). Many of them went through 
countries such as Libya, in which violence is usually 
inflicted on the vulnerable. For women and minors (often 
unaccompanied), these experiences are particularly trau-
matic. That is not ethically acceptable. 
The various initiatives taken at the national and interna-
tional level (Mare Nostrum in Italy, Triton and, very 
recently, the European Border and Coast Guard Agency) 
are certainly positive steps towards saving human lives in 
extreme risk conditions, but much more needs to be done.
Post-migration stressors
Many studies indicate that long periods of detention for 
asylum seekers, lengthy and complex asylum processes, 
unemployment, perceived discrimination and changes in 
socioeconomic roles (including changes of gender roles) 
have a dramatic impact on refugees’ mental health. Thus, 
all possible efforts should be made to improve the quality 
of the asylum seeker centers and accelerate asylum proce-
dures.
HOW UNIVERSITIES CAN HELP IN REDUCING 
POST-MIGRATION STRESSORS
Universities and other higher education institutions can 
play an important role in improving the integration of 
refugees, thus reducing the post-migration living difficul-
ties and possible mental disorders, by providing:
1. Training of experts to help refugee centers and 
hospitals offer high-quality  and culturally accep-
table medical services. Fast tracks for the recogni-
tion of academic and professional titles should be 
implemented, as Sweden has recently done.
2. Education opportunities for young people, facili-
tating access through full recognition of previous 
studies, skills and titles, creating preparatory and 
bridging courses, providing more scholarships, 
etc.
3. Research opportunities for all qualified refugees 
also in collaboration with the initiative Science-
4Refugees by the European Commission.
4. Cultural and sport programs, very useful to facili-
tate integration of young people.
5. Advice to political authorities.
Universities, in cooperation with other civil society orga-
nizations, can prepare projects which can be funded 
 under different European schemes:
� The Erasmus+ program is already funding 
more than 70 projects addressing migration 
issues
� A call on “Migrants’ health: Best practices in 
care provision for vulnerable migrants and 
refugees” was recently published within the 
3rd EU Health Programme 
� The Asylum, Migration and Integration 
Fund (AMIF) (€3.137 billion for the period 
2014-20) promotes the efficient manage-
ment of migration flows and the imple-
mentation, strengthening and development 
of a common EU approach to asylum and 
immigration
Welcoming refugees and organizing their integration into European 
Union society depends on preserving their mental health by  
reducing stressors before, during and after migration. It is a serious 
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OTHER POSSIBLE EU ACTIONS 
Another European tool which could be strengthened is 
the European Voluntary Service, a tool to organize train-
ing for young Europeans and provide short placements in 
refugee facilities inside and outside the EU under the su-
pervision of expert staff members. For instance, Sapienza 
University of Rome, together with the Jesuit Refugee 
Service/Italia, has recently started to promote volunteer 
placements for medical students, which are getting very 
positive feedback. This measure would be very useful in 
improving the quality of the refugee centers and, in this 
moment of crisis for the EU, could help to reinforce the 
European values of peace, reconciliation, democracy and 
human rights for which the EU was deservedly awarded 
the Nobel Peace Prize in 2012. 
CONCLUSIONS
Facing the recent “refugee crisis” and enabling refugees’ 
integration into the EU in good mental condition is a 
serious challenge. It is also an opportunity to remember 
our history and behave according to our values.  
Author
PROF. MAURIZIO MARCECA
President | Italian Society of 
Migration Medicine 2016-2020;  
Department of Public Health and 
Infectious Diseases | Sapienza 
University of Rome | Italy
Author
PROF. DR. LUCIANO SASO 
Vice-Rector | European University 
Networks | Sapienza University of 
Rome | Italy
WORLD HEALTH SUMMITYEARBOOK 2016 2726
Migration and Refugee Health
ESSAY
M
igration, mobility and globalization processes in 
the 21st century have contributed to the rap-
prochement of populations, transfer of cultural 
practices and values throughout the world. Questions of 
belonging, similarities and differences of one’s own 
cultural practices become increasingly relevant in a world 
of comprehensive globalization. These phenomena 
require nations and individuals to understand each other 
not only at an economic and political level but also to 
grasp the complexities of each other’s histories, cultural 
inheritances and narratives.
We witness processes of diversification and homogeniza-
tion at the same time. As a result, some anthropologists 
have even challenged the concept of culture, shifting their 
focus instead to “dynamic processes” being influenced by 
and influencing cultural practices. The current refugee 
crisis in Syria, Iraq, Lebanon, Turkey and Europe has put 
the spotlight on this new and complex dimension of cul-
tural interaction.
Migrant populations include temporary migrants, refu-
gees, asylum seekers and “illegal” or “undocumented” 
migrants. According to the International Office of Migra-
tion, they assisted about 58 million migrants from 2011 
to 2014 (IOM 2015) and 2015 saw the displacement of 
over 4 million people from Syria due to civil war. In addi-
tion, according to a release from the United Nations High 
Commissioner for Refugees, 65.3 million worldwide are 
currently forcibly displaced and 34,000 people are forci-
bly displaced daily due to conflict or persecution. Europe 
and particularly Germany are the destination a large 
share of migrants from the wider Middle East and Africa 
aspire to reach. Most migrants and all refugees brave 
extremely perilous conditions to travel to countries with 
cultures, values as well as healthcare systems very differ-
ent from their countries of origin. For refugees, who are 
fleeing war, political upheaval and desperation, the situa-
tion is particularly precarious. Most of them arrive in 
Europe with multiple traumatic experiences.
But in the end, practically all migrants have health issues 
that need to be addressed. Many of them, for instance, 
faced violence and physical threats (women are at higher 
risk) during their journey. Furthermore, migrants fre-
quently have to grapple with new health-related issues 
following their settlement in their host country. Hostility 
and lack of cultural awareness from the local inhabitants 
can lead, for example, to a worsening of migrants’ mental 
health following social isolation, poverty, loss of status 
and insurmountable challenges. Under such circum-
stances, any traumatization tends to become a long-term 
health issue. Such specific problems come in addition to 
communicable diseases like tuberculosis and hepatitis 
that can be developed due to the perilous journey and the 
change in environment.
Many migrants also suffer from non-communicable dis-
eases like high-blood pressure or diabetes. Additionally, 
migrants often live in poor conditions since they are more 
likely to be offered employment in jobs that are “dirty, dif-
ficult and dangerous” (IPPR 2006) with minimal basic 
occupational safeguards and workers’ rights (EC 2007). 
This situation that is new in its sheer dimension for most 
of the host countries raises important questions about the 
relevance of different cultural backgrounds in health pre-
vention, delivery, care and health policies.
 
In order to continue to play their role properly in the 
interest of public health in general healthcare systems, 
receiving countries must take this complexity into account 
and – in part – adapt accordingly. Healthcare providers 
must be assisted by services that facilitate culturally sensi-
tive healthcare as recently stated by the Regional Commit-
tee of the World Health Organization (WHO) European 
Region. At the same time, in order to boost the cultural 
competency of healthcare providers, curricula will have to 
be amended accordingly.
Our ambition should be to optimize existing healthcare 
systems through new, culturally sensitive capacities of 
communication. To achieve this important goal, a 
workshop entitled “Migration, Cultures and Health” 
was held on this topic at the World Health Summit 
2016. The objective of this workshop was to attract at-
tention to the need for cultural awareness and tolerance 
in the provision of healthcare to refugees and migrants. 
There is still a big gap between the understanding of 
cultural diversity by healthcare providers, including 
medical staff, politicians and NGOs, and the results 
achieved in the field. Overcoming the existing short-
comings would not only mean an objective optimiza-
tion of existing healthcare systems in the interest of all 
but will also contribute to a reasonable policy of 
integration of those migrants who have a long-term 
perspective to stay.
The arrival of migrants from different cultures is a challenge  
our healthcare systems must acknowledge and overcome.  
If they are to play their proper role, doctors and other healthcare  
providers in receiving countries have to take into account the  
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The call for better cultural competency at all levels in the 
healthcare sector resounded throughout the workshop. 
Clinics and health organizations need to examine their 
cultures, a process which has already started in various 
places. For example, the German Commissioner for 
Immigration, Refugees and Integration published a much 
requested brochure on dementia-related illnesses, and 
the Charité – Universitätsmedizin Berlin initiated the 
“Woman to Woman” program, aiming at reducing cul-
tural misunderstandings by holding seminars in the 
homes of migrant patients. Such programs exist, but in 
small numbers. They need to be increased and need to 
encompass the whole healthcare spectrum to achieve 
sustainable improvements and mutual understanding.  
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It might be a poverty reduction strategy for the migrant 
and their country of origin, but some politicians seem to 
focus on the possibility that migration may be impover-
ishing the host country.
No, because migrants very often begin by taking jobs that 
locals don’t want. I mean, how many Germans do you 
have who are willing to work in the kitchen or to mop 
floors or take care of the sick and the elderly? It’s a myth 
to think that migrants are coming to take your jobs. They 
will fill in the areas where you don’t have enough workers. 
Have you found it an uphill battle to make the case that 
granting access to health coverage to migrants as soon as 
they arrive is a good idea?  
It’s an ongoing challenge. Thailand is a good example. Thai-
land has 3 million migrants from Myanmar and others 
from Laos and Cambodia. But they have given healthcare 
access to all migrants and in many ways I think they have 
benefited from it. They have a healthy workforce now, a pro-
ductive workforce – they depend on these migrants. The 
“ It’s a megatrend of  
the century”
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In a lot of discussions, the words “migrant” and “refugee” 
overlap. Part of the discussion about the recent arrival of 
refugees to Germany concerns the economic benefits, 
which obscures the right of people to be refugees, regard-
less of their economic utility. How do you make the case 
for that pure right of movement in the current situation? 
Swing — The International Organization for Migration 
has its own view on this – and I think it’s a widely shared 
view – which is that every refugee is a migrant, but not 
every migrant is a refugee. In other words, refugees are a 
category of migrants even though they are forced 
migrants. So, of the 244 million people the UN says are 
international migrants, you have 23 million refugees, 
which means that refugees are about 9% of all migrants.
Now, I’m sure some of our colleagues in the UN 
system might not like that definition. Part of the tendency 
here in Europe, given the large number of persons com-
ing in from Africa and the Middle East, has been to say 
that everybody who doesn’t qualify as a refugee under the 
1951 Refugee Convention is an economic migrant.
Well, that’s too simplistic. Migration is quite com-
plex. You have in that group, for example, tens of thousands 
of unaccompanied minors. Germany alone has apparently 
about 55,000. You have victims of trafficking, you have 
pregnant women on the move, you have the sick and the 
elderly and you have, for example, Syrians who are simply 
going north to Scandinavia to join their families. They are 
not really refugees as such. But they still have rights. 
The international community is planning to meet in New 
York in 2018 to establish a global compact for safe, order-
ly and regular migration. That doesn’t leave a lot of time 
to sway the public discourse in favor of migration’s bene-
fits. What are some of the strategies you think people can 
use to change the nature of discourse?
First, all of us in positions of leadership, whether it be in 
government, or in NGOs, or in an international organiza-
tion such as IOM, we have an enormous responsibility to 
begin to stand up and say what we all know: namely, that 
migration is a natural, necessary and potentially enriching 
phenomenon; that migrants are human beings deserving 
of respect, humane treatment and deserving of our thanks 
for their skills, their innovation, and their social and cul-
tural enrichment, whatever their status may be. Yet, many 
migrants lack equitable access to health services, and many 
are exposed to poor living and working conditions and 
occupational health hazards that make them vulnerable to 
ill health. Health professionals who know well that ensur-
ing migrants access to health services is a sound public 
health policy have a role to play in that. 
Secondly, persons in the media who are spreading 
the word should offer people another approach, another 
angle, humanizing migration. We are engaging with 
social media and have, for example, an “I am a migrant” 
social media campaign that’s designed to showcase 
migrants who are doing interesting things. We are trying 
to do more to talk about migrant contributions to society, 
both in the host country and the country of origin, to 
show that historically migrants have always been over-
whelmingly positive: They are the original agents of 
development. To quote the economist John Kenneth Gal-
braith, “migration is the oldest action against poverty.”
Does that poverty reduction strategy work? 
It does. Global remittances amount to US $500 billion, 
and last year the total foreign direct investment was 
something like US $654 billion globally. So it’s almost as 
much as all foreign direct investment – and twice as much 
as foreign aid. For countries like El Salvador, for example, 
probably 30% of its GDP comes from remittances. 
“ It’s a myth to think  
that migrants are coming 
to take your jobs.”
sooner these people get jobs, the sooner they are going to 
pay taxes. In the end they pay back more in taxes than 
they’ll ever get from the public services. The healthier they 
are, the better they contribute to the prosperity of their 
countries of origin and destination. It is a win-win situation. 
So the economic case is the most effective argument? 
It is an argument amongst others. Migrants’ health bridges 
rights, public health, and development, plus the contribu-
tion of diversity. Diversity does so much in terms of entre-
preneurial skills, in terms of dynamism, languages, culture, 
all sorts of impulses that enter a society. Diversity has made 
so many countries very dynamic societies. I mean, my own 
country continues to benefit from inflows every year of mi-
grants. In fact, we would be in the same situation as Europe 
– with more people dying than being born – if it weren’t for 
migration. The same thing goes for Canada. 
Are the historical examples applicable? In the German 
case, there were 12 million migrants right after WWII, but 
all of them spoke German. You have a different integra-
tion challenge today. 
There is a psychological adjustment that countries like 
European countries are having to undergo, and it’s not 
just a question of getting over refugee amnesia.
European countries have peopled the world for 
three centuries – colonies, investment, trade, academic 
exchanges. And now we are becoming a continent of des-
tination rather than just a continent of origin, which 
means rather than you sending your people out, people 
are coming to you. That’s always a little disconcerting.
This is where the media and governments have such 
a big role to play. We try to explain why these people are 
coming, who they are, and how one can prepare to receive 
them. Both communities – the host communities and the 
migrants – have a responsibility to make integration 
work.
Do you have any particular examples in mind that are 
really best-case scenarios or models? 
I hesitate to use Canada, because when you say Canada 
Europeans say, “look, they’ve only got one neighbor and 
they’ve got two big oceans on either side.” But if you want 
to take an example of who has done it and done it well, 
when the new Prime Minister, Justin Trudeau, was cam-
paigning, he said, “If I am elected, we will bring in 25,000 
Syrian refugees.” Then he went on to say, “We will bring 
them in not as refugees, but as future Canadian citizens.” 
That already sets a different tone for people. He sent his 
minister John McCallum out to provincial governments 
and talked to the mayors. That was, I think, done in a 
well-prepared way. It’s a bit different from the European 
situation, but it has elements that could be adapted. 
Sometimes people see this as a temporary crisis, but I’m 
hearing you say migration isn’t going away. 
No. It’s a megatrend of the century.  
INTERVIEW
WILLIAM LACY SWING  
Director-General | International  
Organization for Migration | Switzerland 
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HEALTH IN NUMBERS
 Migration and  
Refugee Health: 
From Care to Policy
STATEMENT ON THE MOVE
The current inf lux of migration – the biggest since the end of World War II – is 
putting migrant health issues at the top of government agendas. Basic care is no 
longer enough. We need new concepts for adapting health policy strategies that 
take into account transformative processes, both in migrant countries of origin 
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“ There is a whole 
 universe of  fantastic, 
unexpected new 
 findings out there”
From smartphones to delivery drones, technology 
is changing the way we think about public health. 
But are its benefits – and risks – evenly distributed? 
And what can be done to improve care for all the 
people of the world? At the World Health Summit, 
four leading figures from different health-related 
areas gathered to discuss the way technology can 
best be applied to pressing problems of public health 
and other challenges facing today and the future.
DR. MANUEL DELGADO
Secretary of State of Health | Ministry of 
Health | Portugal
DR. YUKIYA AMANO
Director-General | International Atomic 
Energy Agency | Austria
DR. MATSHIDISO REBECCA MOETI
Regional Director for Africa | World 
Health Organization | Botswana
PROF. DR. PASCALE EHRENFREUND
Chair of the Board | German Aerospace Center |  
Germany
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DR. MANUEL DELGADO 
Secretary of State of Health | 
Ministry of Health | Portugal
Let’s start by talking about the uneven distribution of tech-
nology, and what the needs are in developing and devel-
oped countries. Does the international community have its 
priorities straight when it comes to funding, or is too much 
being spent on solutions to first-world problems? 
Moeti — In the African region it’s recognized that many 
people are taking advantage of technology, IT in particu-
lar. They still have a long way to go for technology to be a 
regular feature at the household or public health system 
levels.
Electronic health and mobile health, starting with in-
formation collection, surveillance and data gathering are 
important in our region. It’s critical to have data systems 
that enable rapid awareness that a strange pattern of illness 
and death is occurring somewhere, understand what this 
means, and trigger an investigation and response, for ex-
ample. We see this as a huge opportunity waiting to be bet-
ter exploited in the African region. 
Amano — Yes, distribution of resources is uneven. But 
we are doing a lot to change that. Just take, for example, 
cancer. On the African continent, 28 countries do not 
have any cancer diagnostic equipment or radiotherapy 
equipment. Cancer patients come to the clinic too late, so 
we cannot provide life-saving treatment. So this is unfair, 
this is uneven, and this must be corrected.
What can we do as an international organization? I 
think the different organizations need a different man-
date and we need to cooperate. International organiza-
tions cannot do everything, so we need to cooperate with 
government, NGOs and private companies. We can pro-
vide basic equipment, but not much. What we are better 
at is providing training. We can receive trainees and what 
we can do is use our network to place trainees into other 
countries.
Are these devices cost-effective? Are they expen-
sive? Yes, they are. The basic diagnostic machine can 
cost from US $1 million to US $2 million. More sophis-
ticated machines can be around US $10 million. But if 
you have one machine, you can diagnose 3,000 people a 
year.
We were involved in the diagnosis of Ebola, and 
that is much cheaper. One kit to detect the Ebola virus 
was around €50,000, and that is a lot. With one kit, 
though, we can detect the Ebola virus in 3,000 people. If 
you consider the economic loss from Ebola, from cancer, 
this is a very good investment, I think. 
Delgado — We have to put resources in perspective. I'm 
coming from a country where frequently there are two 
experiences. In Portugal, all the Portuguese have access to 
technology. But we are linked to former colonies in Afri-
ca, and we see people coming to Portugal looking for help 
to treat problems they can’t in their countries.
In a small country like Portugal, we have some prob-
lems with the distribution of these kind of treatments and 
technologies. The more treatments we make available, the 
more people will use them. So we are always trying to be 
diplomatic around the doctors. If we politicians say “no, 
this equipment cannot be used in these circumstances,” 
they say, “But I am the doctor, not you.” That may be true, 
but we need to promote the creation of criteria that are 
independent of stakeholders to promote the correct use of 
these kinds of treatments. 
Can you give an example? 
Delgado — Take intestinal cancer. We decided in Portu-
gal to promote colonoscopies for people over 50. What 
happened was that the number of examinations increased 
more than 600%, with marginal benefits in terms of de-
creased mortality. Of course, the government spent a lot 
of money on these examinations.
Now we are in a very difficult situation, because if 
we introduce stricter criteria to promote the better use of 
colonoscopies, people will be unhappy. 
Amano — I have personal experience on this: I became 
the director of the International Atomic Energy Agency 
in 2009 and attended the first conference as director in 
2010. I chose to address breast cancer. People thought this 
new director is a strange guy – he doesn’t talk about nu-
clear power generation, but will talk about breast cancer. 
They were talking about which age women need to go to 
screening, and there was a heated discussion. It’s a serious 
issue.
But I said, “you are talking about which age women 
have to start going to screenings, but in African countries, 
which I have visited, people do not have any access to 
mammograms.” Some people cannot tell their husbands 
that they have breast cancer – they leave the home and 
just die.
So there are two realities. On one hand, you could say 
people are suffering from an overdose of access to cancer 
diagnosis. On the other hand, there are those who have no 
access and are just dying without being treated and diag-
nosed. We need to address the contradiction: In develop-
ing countries, they don’t have this luxury. They often can-
not afford any access. So we need to support them. 
Help them establish expertise, or help them acquire the 
technology? 
Moeti — I think you need to guide how they invest. Coun-
tries have asked WHO to advise them on how to navigate 
the many different offers from private companies that are 
approaching the ministries, the different decision-makers 
within the system, offering deals. “I have got this for you, I 
have got that for you.” I think they run the risk of purchas-
ing and contracting for technology or equipment which is 
not the most cost-effective for their needs.
Amano — This is exactly what we are doing together with 
the WHO. Before these countries buy expensive equip-
ment, they have to establish their first dedicated cancer 
center, then they have to be able to train their own trainees. 
Otherwise they cannot be sustainable. 
Ehrenfreund — I just have to talk a little bit from a differ-
ent angle, since we are not really providing instrumenta-
tion. But we have a lot of cooperation with the United 
Nations and other organizations. When there are major 
disasters, like the recent Hurricane Matthew in Haiti, we 
deliver data immediately for an immediate response – 
within hours, we actually deliver data that helps provide 
humanitarian aid in those crisis regions. So from space 
we can really help when there is a need.
In the long term, when you have detailed satellite 
data on agriculture and climate you can also understand 
why people have to leave home in the first place. If we 
could use those 30 years of data in order to look at trends, 
perhaps we could stop the migration by improving the 
situation locally.
Telecommunication satellites can also promote 
healthcare solutions for remote locations. I think space 
can really contribute a lot to solving global challenges, in-
cluding healthcare. The United Nations Office for Outer 
Space Affairs has, for instance, a network called the Basic 
Space Technology Initiative. They are actually teaching 
developing countries how to interpret satellite data, for 
instance, and how to build small satellites. We and NASA 
and many other organizations help people in developing 
countries look at their future and their health environ-
ment from space. 
“ The more 
 treatments we 
make available, 
the more people 
will use them.”
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Our idea is to develop a national health service applica-
tion. If you have a medical emergency you need to go to 
an emergency room, for instance: In Lisbon we have four. 
You can use your phone to see which one has the shortest 
waiting time. You can check waiting lists for surgery, 
waiting times for a patient consultation, all on your phone 
or computer. 
Another idea we implemented recently is the pre-
scription of drugs without paper. The doctor inputs the 
data directly into a computer and the patient receives an 
identification number. With this identification number 
he can go to any pharmacy and collect the drugs he 
needs. So it’s more safe and eliminates corruption.
Dr. Ehrenfreund, are scientists listened to in the political 
realm? How can researchers make more of a contribution 
to the public debate?
Ehrenfreund — I think that scientists are always trying 
to find new ways of defining new research avenues, but 
what they need is, of course, support for grants. You can 
trigger research in a particular direction when you have 
special funding nationally but also from the  EU or other 
organizations.
And where does that funding need to be? What are the 
main crises that need to be addressed right now by the 
public health community? 
Amano — I would say that there is too little attention to 
cancer. There is this perception that this is a disease that 
just affects people in developed countries. This must be 
corrected. We want to promote more training and coop-
eration, perhaps using satellites and IT to get doctors in 
African countries connected to their colleagues or Cana-
da, or Sweden in the form of virtual universities or educa-
tional programs from the IAEA.
Ehrenfreund — At the DLR [German Aerospace Center], 
we are not directly involved in healthcare as such, but I 
want to make a real call for basic research. You need this 
kind of research in order to have radical innovations. We 
can only achieve real breakthroughs when we are not too 
program-oriented.
I know this, from having previously led a research 
funding organization: In medicine, you need to fund the 
whole innovation chain in order to be successful. 
Hurricane Matthew is a great example and I’m glad you 
brought it up. Who do you deliver assistance to? Every-
body here, whether you’re representing an international 
organization or government, has to have partners you 
work with. Is that collaboration good enough in the 
healthcare arena?
Ehrenfreund — We are working with the United Nations 
in that case. We have a satellite crisis management team 
close to Munich. And they deliver immediate data to the 
UN when it’s requested.
Moeti — We could probably use the data better if we un-
derstood where within the UN this data could be avail-
able. For example, I’m interested in data that would help 
predict disease outbreaks that might occur because of 
climate trends, weather pattern changes and the like. We 
could use something like that in a forward-looking way, 
in order to help countries prepare for and plan for shifts 
in the patterns of diseases.
I’m sure that more data on urban areas could also 
help. Let me be frank – we were caught by surprise by the 
outbreak of yellow fever that very soon spread to urban 
areas in Angola and the Democratic Republic of Congo. 
Everybody was petrified when we realized that the think-
ing about yellow fever and the strategy for prevention, at 
least in the African region, was based on how people were 
living 20 years ago.
We did not take into account the type of ecology that 
has evolved over the years with the rapid urbanization in 
African countries combined with the trends in the climate, 
which together have combined to really create a good envi-
ronment for unusual patterns and unusually severe out-
breaks of diseases like yellow fever and dengue. I think that 
having a better understanding of where such predictive 
data might be available, which you might have and could 
help with use in the UN and also, then, in the countries, 
would be helpful. 
So maybe I can ask a politician: How can technology be 
better applied to healthcare problems? 
Delgado — It’s not an obvious thing but the health infor-
mation system is technology, perhaps not applied to 
treatment but applied to knowledge. In Portugal, we are 
very, very focused on this because we think that the more 
access patients have to treatment and to their medical 
records the better.
DR. YUKIYA AMANO
Director-General | International 
Atomic Energy Agency | Austria
PROF. DR. PASCALE EHRENFREUND 
Chair of the Board | German Aerospace 
Center |  Germany
“ Quite often, 
 people love to 
have the most 
advanced device, 
but we tell them 
it,s not always  
a good idea.”
“ Space can  really 
contribute a  
lot to solving 
 global  challenges, 
 including 
 healthcare.”
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system treats you, independent of the level of complexity 
or gravity of this disease. But we cannot use all kinds of 
new technologies before an agency assesses their effec-
tiveness. 
So restriction and control should be based on efficacy, 
not cost? What if there were a fantastic new techno- 
logy that was very expensive but better than the old 
technology? 
Delgado — Last year, a new drug for the hepatitis C virus 
was approved. For each treatment, the initial proposal of 
the industry was a significant amount per patient to cure 
hepatitis C. Not to manage, but to cure. The government 
negotiated directly with the company in order to bring 
down the price.
Moeti — So you have to go off the record. 
Delgado — I can tell you we decided to negotiate, for the 
first time in Portugal, risk-sharing between the govern-
ment and the company. We pay for the treatment, but 
only if the patient is really cured. And we have a simulta-
neous control made by the government and the company 
in order to define that with laboratory tests. If it works, 
and we pay for 98% of the patients, the company stands to 
earn so much. 
Moeti — That’s interesting. 
Dr. Amano, when you’re proposing a country buy a very 
expensive radiotherapy device, what are your cost-benefit 
analyses? 
Amano — We are not proposing very expensive equip-
ment. Quite often people love to have the most advanced 
device, but we tell them it’s not always a good idea. For 
example, for linear accelerators, if their electricity is not 
stable it doesn’t make sense to buy very advanced ones.
But we do not recommend starting from zero. 
Nowadays, medical treatment is very advanced and 
nuclear medicine is advanced, so why not start using the 
experience of other countries? All people should be 
entitled to the best possible care. What is important is 
suitable, quality and effective care, including cost-effec-
tiveness. So the technology must be reasonably 
advanced, but there is no need to aim at the most 
advanced, most expensive thing. For example, in Japan, 
heavy particle treatment is very effective for brain 
tumors, but the equipment costs €300 million. There are 
very few countries who can afford this. However, a €1.5 
million machine can provide effective treatment for 
thousands of patients over many years. But in the end, 
it’s the country that decides. 
Moeti — I was very interested in the question that Secre-
tary Delgado raised about negotiating with pharmaceu-
tical companies and the need to keep that information 
confidential. There is a strong drive from our region for 
transparency and information sharing about pharma-
ceutical prices. Joint negotiation with the pharmaceuti-
cal companies – so that you don’t find this one here pay-
ing a price very different from South Africa right next 
door to each other – seems like a good idea. What could 
be the role of inter-country joint approaches? The more 
countries that can join in at affordable prices, the more 
the market is growing. I think it’s a very interesting pos-
sibility. 
Dr. Ehrenfreund, what about basic research? In light of 
the problems the world faces, is it worth spending money 
on discovery-based science?
Ehrenfreund — There is huge value in space and also ba-
sic research. When we conduct experiments on the inter-
national space station, we have some main questions 
which we want to answer, and sometimes the results are 
very new and unexpected. We have new findings on oste-
oporosis because of bone loss in microgravity and weight-
lessness. We have new insights into cardiovascular diseas-
es and the orientation of the eye. And you have certainly 
also heard that there are microbes which get very virulent 
in space. 
On the International Space Station, there are a lot of 
radiation studies. And you can extrapolate from those re-
sults for cancer therapy on Earth. That also applies to tech-
nology, too – robots which we use in space can actually 
then be used for medicine here on Earth. But we also 
looked at the spatial orientation of astronauts in zero grav-
ity with a 3D eye-tracking device that is now used in laser 
surgery for eyes. 
What I’m saying is there are a lot of spinoffs and un-
expected results from basic research. So you should not 
forget that there is a whole universe of fantastic, unex-
pected new findings out there which can be linked to re-
search on Earth and help healthcare on our planet too.  
DR. MATSHIDISO REBECCA MOETI
Regional Director for Africa | World 
Health Organization | Botswana
Delgado — It’s true that in developing countries they have 
no antibiotics, but in Portugal right now it’s the excessive 
use of those that is a big problem. At the moment, some 
hospitals present mortality rates from infections that are 
higher than 10 years ago. The situation is so bad it’s become 
a political issue. The challenge for industry is to develop 
new antibiotics. But the companies say “well, it’s important, 
but there’s not enough profit there – we need public invest-
ment to develop new antibiotics.” 
Moeti — I think antibiotic resistance is even more dan-
gerous for low-income countries. As these antibiotics be-
come ineffective in the wealthier countries, the market 
reasons for continued production disappear, which 
means that developing countries no longer will have 
access to effective antibiotics. Some of the most common 
antibiotics are simply not available.
Policymakers are starting to think about some sort of 
global partnership, to create the incentives for pharmaceu-
tical companies to invest in the research and development 
of new antibiotics.
Then there’s the issue of counterfeit or low-quality 
drugs, which are frequently on sale in low-income coun-
tries all over the world. So again, there is demand for 
research and development to find solutions to this 
 counterfeit drugs problem. 
And then investment in a time of austerity and pressure 
on funding, you’re asking for basic science funding, you’re 
asking for a very applied use. Is that going to come from 
taxpayers and governments?
Delgado — It’s very difficult to have a solution for this. The 
question for the industry is very easy to understand: If we 
use drugs and technologies without any kind of control, at 
a certain moment, the system goes broke. But if we use 
these technologies with control, with health technology as-
sessment, all sides benefit – the governments, the patients, 
and the industry too. It’s much more sustainable to manage 
care. It's a compromise. 
That kind of rationing can be politically unpopular. Pa-
tients want unlimited access to whatever care they might 
want or need. 
Delgado — It is not a good idea to have free access to 
health providers. We prefer a national service, free for ev-
erybody, but with some limits. If you have a disease our 
“ Developing 
countries  
no longer will  
have access  




From age-old nemeses like malaria and tubercu-
losis to modern adversaries like Zika and  Ebola, 
communicable diseases are one of the greatest 
challenges the public health sector has to  
face. The consequences of failure are tremendous: 
2014’s Ebola outbreak cost an estimated US 
$1 billion to bring under control.
The solutions, experts say, are within our grasp: 
Funding is needed for new vaccines, education 
programs to emphasize the importance of  
hygiene, and international coordination to deal 
with disease outbreaks promptly. 
A broader perspective is needed: “When we think 
about infectious disease, we have to get out  
of the biomedical model and talk to economists, 
geologists and sociologists,” said Peter J. Hotez, 
President of the Sabin Vaccine Institute. “It’s  
not easy for us to do so because in the medical 
world we’re quite siloed.”




he Ebola crisis was not only a humanitarian trage-
dy, but also the straw that broke the camel’s back 
and led politicians and economists to refocus not 
only on humanitarian issues, but also on financial 
impacts. Expert groups were gathered to develop new 
ideas targeted at nullifying or at least reducing the risk of 
pandemics. It was generally agreed upon that increasing 
urbanization and globalization significantly enhanced 
the risk that a local outbreak progresses into an endemic 
with risk of a pandemic if countermeasures are not taken 
immediately. In these calculations, not only were direct 
costs for diagnostics, drugs, vaccines and medical care 
considered, but also indirect losses due to leave of 
absence, illness or disability and even losses in trade, 
transportation and tourism. A common theme was active 
prevention, which was identified as the most cost-effi-
cient option. Different reports calculated an average an-
nual loss of US $30 to $50 billion due to new pandemics. 
The rather short pandemic caused by the severe acute re-
spiratory syndrome (SARS) virus in 2003 alone account-
ed for some US $54 billion in losses. Today, a pandemic of 
the size of the Spanish flu of 1918, with some 50 million 
deaths when the global population was less than 2 billion 
people, would amount to an estimated US $3 trillion and 
a 5% decline in the worldwide gross domestic product 
(GDP). Over time, the idea of infectious diseases as being 
of both human and animal origin has also gained increas-
ing awareness. In the past, some 70% of all newly emerg-
ing pathogens have jumped from animals to humans. 
THE “NEW” CULPRITS
The Ebola endemic was virtually restricted to three West 
African countries – Guinea, Sierra Leone and Liberia. 
The few cases that had occurred up to the end of 2013 
were more or less ignored. After all, small Ebola out-
breaks had come and gone before. However, this time 
things were different. Towards the end of 2014 more than 
20,000 people had fallen ill and nearly 8,000 had died. 
The incredible engagement of non-governmental organi-
zations, notably Médecins Sans Frontières (MSF), togeth-
er with local health workers, prevented the worst. As late 
as August 2014, the World Health Organization (WHO) 
declared a global health emergency – too late for rapid 
termination of the crisis. In January 2016, when almost 
30,000 people had fallen ill and almost 12,000 people had 
died, the WHO finally claimed the region Ebola-free. 
Financial losses for the area amounted to more than 
€1 billion and a 12% decline in GDP. Despite the inherent 
fear that the endemic could turn into a pandemic, this 
worst-case scenario was prevented. Of course a vaccine 
would have been a game-changer, and indeed some can-
didates had been developed in the aftermath of 9/11 
under the umbrella of the US biodefense program. Yet, 
these vaccine candidates could not be pushed through the 
clinical pipeline because of the absence of disease. Only 
towards the end of the Ebola outbreak in 2015 did a clin-
ical efficacy study which showed promising results 
become possible.
Soon a new disaster emerged. The Zika virus had entered 
Latin America. This virus is transmitted by Aedes mos-
quitos. In contrast to the Anopheles mosquitos responsi-
ble for transmission of malaria, the Aedes mosquitos have 
adapted to urbanized areas. Because they are quite resis-
tant to pollution and cold temperatures, they have spread 
from tropical and sub-tropical areas to the Middle East, 
India, the southern parts of the US and Europe. Although 
the Zika virus was identified in Uganda in 1947 and 
appeared in sporadic outbreaks in subsequent decades, it 
was more or less ignored because in most cases infection 
produced only mild symptoms. During its 2015 and 2016 
spread throughout Brazil and some other 30 Latin Amer-
ican countries, it soon became clear that the Zika virus 
can cause neonatal microcephaly when it infects a wom-
an during pregnancy. This time, the WHO reacted 
promptly, calling a global health emergency at the end of 
January 2016. By March 2016, around 1.5 million sus-
pected or real cases of Zika disease and some 4,000 cases 
of microcephaly had been recorded in Latin America, 
with the majority in Brazil. 
In parallel and more or less unrecognized, another viral 
pathogen, which is also spread by the Aedes vector, 
emerged. The dengue virus is responsible for at least 100 
million cases of illness and 20,000 cases of deaths annual-
ly. A dengue vaccine has been licensed in Mexico, the 
Philippines and Brazil very recently which, although not 
perfect, provides some hope that this disease can be 
brought under control. Although a Zika vaccine is not yet 
on the horizon, the Zika virus belongs to the group of 
Flaviviruses. Together with dengue, these viruses also 
cause yellow fever, FSME and Japanese encephalitis. For 
all these diseases, vaccines have been developed. So a 
blueprint for the development of a vaccine against the 
Zika virus is already available. The fact that the availa- 
ility of a vaccine does not prevent outbreaks as long as it 
is not widely used has been re-emphasized by the recent 
outbreak of yellow fever in Luanda, Angola’s capital. 
There, yellow fever has rampaged since December 2015 
with some 500 confirmed cases and 200 deaths so far. By 
now, some 6 million people have been vaccinated against 
yellow fever in the Luanda area with the hope that further 
spread can be prevented. However, the vaccine stockpiles 
are almost empty, emphasizing the need for international 
vaccine stockpiling. 
THE “OLD” CULPRITS
The dengue pandemic reminds us that in parallel to new-
ly emerging diseases, existing pandemics are equally 
threatening and cannot be ignored just because they have 
been around a long time. Notably, the three major killers 
– tuberculosis (TB), Acquired Immunodeficiency Syn-
drome (AIDS) and malaria – are responsible for millions 
of infections and deaths. With a morbidity rate of 9.5 mil-
lion and a mortality of 1.5 million in 2014, TB remains a 
global threat which is further exacerbated by increasing 
occurrence of multidrug resistance. In 2014, the human 
immunodeficiency virus (HIV) infected some 2 million 
individuals, causing 1.2 million deaths. In 2015, there 
were roughly 214 million malaria cases, leading to nearly 
450,000 deaths. It has been estimated that the increasing 
incidences of drug-resistant TB, malaria and AIDS will 
cause financial losses in the order of US $100 trillion over 
the next 35 years. An efficient vaccine is neither available 
for AIDS nor TB, and the recently licensed vaccine 
against malaria is far from satisfactory. 
WHAT NEEDS TO BE DONE?
The world needs to be better prepared for infectious dis-
eases. Newly emerging diseases need to be recognized 
and countered immediately and existing infectious 
threats need to be combatted more rigorously. One study 
proposed investing some US $4.5 billion per year, split 
into US $2–$3 billion for early surveillance and counter-
action; US $1 billion for research and development and 
US $150 million for establishing and sustaining these ac-
tivities. Compared with estimated losses of US $30–$50 
billion annually due to infectious disease outbreaks and 
pandemics, that sum looks like a bargain. The major 
activities to be put immediately into effect include: 
 ȣ Functional clinics and basic medical care, inclu-
ding better vaccination and hygiene programs
 ȣ Global organization and stockpiling of interven-
tion measures
 ȣ Global surveillance to rapidly identify emerging 
hotspots, ideally before the epidemic starts
 ȣ International centers for global health security 
measures
 ȣ Strengthening of research and development for 
novel medicines and interventions
 
Only if we learn our lesson from the Ebola crisis will we 
be better prepared for the next outbreak.  
Infectious diseases remain a challenge. The Ebola crisis was 
a wake-up call for better preparedness. Improved prevention 
measures will be costly, but are a bargain compared with  
projected annual losses on the order of US $30 – $50 billion. 
LESSONS  
LEARNED FROM 
EBOLA TO ZIKA 
Author
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he 2014 Ebola epidemic in West Africa and the 
recent Zika epidemic are painful reminders of the 
dreadful toll infectious diseases can take on popu-
lations and economies. They have shown that countries 
are not well prepared to respond to global epidemics 
caused by emerging pathogens. Though a global collabo-
rative effort has allowed us to move from having no 
vaccines against Ebola to several candidate vaccines, the 
Ebola crisis should serve as a wake-up call that we need to 
change the access model to innovation. 
Immunization programs are not only critical to improve 
our response system, but are also one of the “best buys” 
when it comes to public health and socioeconomic devel-
opment. Vaccination is the most cost-effective health-
care intervention after the provision of safe drinking 
water and sanitation. In order to secure the highest public 
health and economic impact, vaccination programs 
should reach those in greatest need through broad 
programs implemented in the shortest time possible. This 
requires challenging the conventional vaccine introduc-
tion model.
In this model, innovation is steered by the medical needs 
of wealthier countries which can afford the launch prices 
necessary to finance and incentivize both innovation and 
production scale-up. As a consequence, new vaccines are 
launched first in developed markets in small volumes and 
at a competitive price, and made available in low- and 
middle-income countries (LMICs) significantly later (i.e., 
8 to 10 years) at a lower price once the innovation cost has 
been recouped. Access in poorer countries thus tends to 
be delayed, and diseases which affect these countries only 
– such as Ebola, Chikungunya, dengue or Zika – are often 
neglected.
DENGUE
Dengue fever – for which half the world is at risk, mainly 
in LMICs – propelled Sanofi to adopt a new access model 
to innovation. Dengue is a serious and complex disease 
which mainly affects sub-tropical and tropical regions, 
and which is associated with a substantial socioeconomic 
burden at both individual and societal levels. The inci-
dence of dengue has surged 30-fold over the last 50 years, 
amplified by globalization, urbanization and climate 
change, but the true scale of the disease burden is likely 
underestimated. According to some estimates, the dengue 
burden can be twice as high when considering the broader 
impact of dengue on productivity loss, decrease in foreign 
investment and losses in revenues from tourism. 
The Sanofi dengue vaccine – a live, attenuated, tetravalent 
vaccine – is the only vaccine that has demonstrated 
evidence of clinical efficacy against dengue in clinical 
studies (40,000 individuals enrolled in 15 countries). It 
has been licensed in five countries as of July 2016 (Mexi-
co, the Philippines, Brazil, El Salvador and Costa Rica) 
and has been recommended for use by the Strategic Advi-
sory Group of Experts (SAGE) on Immunization of the 
World Health Organization (WHO). 
POPULATIONS AT GREATEST RISK FIRST
The dengue vaccine, already launched in the Philippines, 
is having its initial introduction in LMICs where the need 
is the greatest and where it can have the greatest impact 
on global dengue burden. Sanofi is introducing the vac-
cine in both the public and the private sectors so as to 
ensure broad access and highest impact from registration 
on. To achieve this, the company is valuing the vaccine in 
a way that balances the cost of innovation against afford-
ability in these LMICs. 
A BOLD AND EARLY ENGAGEMENT
Twenty years ago, long before the results of phase III clin-
ical trials and the vaccine launch, Sanofi committed to the 
fight against dengue through an unprecedented invest-
ment of resources in scientific, technical and industrial 
capabilities. The company acknowledged the magnitude 
of the dengue challenge at its early stages and made a bold 
and uncommon decision: It took the risk to develop the 
vaccine, invest in industrial capacity and prepare market 
launch all at the same time, rather than as a sequence as is 
usually the case. 
Sanofi committed substantial financial resources to den-
gue, including a €350 million investment in a dedicated 
state-of-the-art production plan in Neuville, France. This 
major investment allows the company to produce around 
100 million doses per year, and to supply one billion 
doses over 10 years. Thanks to this early – and risky – 
engagement, Sanofi already has doses available at the 
time of licenses, thus avoiding a time lag between licens-
ing and implementation. 
PAVING THE WAY FOR THE INTRODUCTION OF 
FUTURE VACCINES 
A successful introduction of the dengue vaccine would 
demonstrate to other private sector companies that the 
dengue business model is attractive, and encourage sus-
tained investment in healthcare innovations for LMICs, 
while improving the response system to dengue out-
breaks. Dengue could serve as a model for the introduc-
tion of new vaccines which will be implemented through 
broad vaccination programs. 
The dengue access approach has also created social value 
at local level through the strengthening of in-country 
skills and capacity and the building of public-health col-
laborations. In endemic countries where the clinical trials 
were conducted, Sanofi has developed strong cross-sector 
collaborations, empowered local healthcare providers 
with disease and vaccine knowledge, trained communi-
ties at risk on dengue prevention and upgraded health-
care facilities. This should facilitate future vaccine intro-
ductions.
Today, Sanofi is building on its successful history in de-
veloping vaccines against dengue and other similar flavi-
viruses (yellow fever, Japanese encephalitis), to answer 
the global call to action to fight Zika. Sanofi’s expertise 
and established R&D and industrial infrastructure for the 
dengue vaccine is being leveraged to better understand 
the spread of the Zika virus and to expedite the identifica-
tion of a vaccine candidate. It is, however, critical to un-
derline that Sanofi cannot solve this alone; we need gov-
ernments, international organizations, academia and 
industry partners to collaboratively work on a Zika vac-
cine development project.
MOVING FORWARD TOGETHER 
Because infectious diseases such as Zika know no barri-
ers, common protocols and approaches are needed to 
promote investment and to prevent and cure diseases. 
When there is an immediate and guaranteed market, 
companies have an incentive to invest fast, but when the 
opportunity is longer-term and more uncertain, society 
flounders when struggling to come up with solutions. 
Populations, however, cannot wait 20 years for an essen-
tial cure. Diseases do not pause for us to get the access 
model to innovation right: not addressing this funda-
mental challenge fast enough is putting entire popula-
tions at risk. We thus need to develop more equitable 
access models to innovation that do not forgo long-term 
societal value for short-term returns. Let’s think of it as 
life insurance: Paying a premium today will allow protect 
ing populations who need it most in the long term.
More innovative access models such as the one introduced 
by Sanofi for dengue are needed to allow LMICs timely and 
sustainable access to innovative vaccines and to improve 
the response system to outbreaks. Close international and 
cross-sector cooperation is vital to support an integrated 
approach to infectious diseases and to fight the global 
threat they represent. To go far, we must go together.  
Recent epidemics have shown that infectious diseases know no 
barriers and cross international borders with impunity.  
Immunization programs are critical to improve our response 
system to these outbreaks, but the vaccine access model to 
innovation needs to be flipped to reach those in greatest need. 
We must work together to develop more equitable access  
models to innovation.
FLIPPING THE  
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Building on the expertise of IPIN and on the Laboratory 
for Urgent Response to Biological Threats, as well as on 
dozens of reference centers (national-, regional-, 
WHO-collaborating-, OIE-reference-, hosted in IPIN 
Institutes), the Center for Global Health has established 
the Institut Pasteur Outbreak Investigation Task Force 
(OITF). Upon request from a Ministry of Health or 
WHO, the OITF calls upon experienced interdisciplinary 
teams of IPIN scientists to be rapidly deployed to support 
investigations of outbreaks. Our aim is to better under-
stand emergence and transmission patterns, to limit fur-
ther spread in human populations, to improve emergency 
response management, to enhance preparedness, to con-
tribute to the development or improvement of efficient 
diagnostics and to advance global understanding of 
emerging and re-emerging infectious diseases. 
ACTION NEEDED – BUILDING AND  
MAINTAINING CAREERS OF SCIENTISTS,  
MEDICAL PRACTIONERS AND  
PUBLIC HEALTH PROFESSIONALS
The Ebola outbreak in West Africa highlighted not only the 
dramatic consequences of poor preparedness and weak 
health systems, but also the shortage of trained personnel 
and laboratory-based capacity in areas such as surveil-
lance, diagnostics and medical care. We strongly believe 
that education and training are critical to strengthening 
capacity in a way that improves local responses to 
detecting, monitoring and managing public health threats. 
The IPIN has long-running experience in educating and 
training scientists, medical practioners and public health 
professionals throughout the world through undergradu-
ate, Master’s and doctoral programs that are strongly 
anchored in national educational systems. This is comple-
mented by specific fellowship, post doc and early career 
placements within the IPIN institutes designed to further 
professional scientific development in the countries 
which need this most. 
The Institut Pasteur is launching a new educational initia-
tive: the Pan-African Coalition for Training (PACT) in 
Research and Public Health. This multi-country, 
multi-partner initiative builds on the existing educational 
and training activities of the IPIN. The long-term estab-
lishment of IPIN institutes in Africa will provide stability 
and opportunities for lifetime careers for local scientists 
and practitioners, but we have also developed strategic 
partnerships with key African players.
ACTION NEEDED – ENTERING THE DIGITAL 
SCIENCE AND MEDICINE ERA
The genomics revolution has allowed enormous progress 
in gene sequencing and molecular detection capacity, as 
well as possibilities for personalizing medicine. While 
this puts scientists at the forefront of the “omics” revolu-
tion, it has also highlighted the need for enhanced big 
data capacity and analysis. 
The Institut Pasteur Global Health Genomics Center 
(GHGC) is currently developing a specialized, cloud-
based platform dedicated to data storage, sharing and 
analysis, while samples are collected, referenced and kept 
in local biobanks under well-standardized procedures. 
Local resource hubs throughout the IPIN will enable 
remote access to data and the translation of data- 
ntensive biomedical research to clinical practice across 
the IPIN, enhancing capacities to respond to infectious 
disease threats. The GHGC also offers a training and 
education framework with a particular focus on bioinfor-
matics, biostatistics, computational and modeling skills 
(also part of the PACT initiative). 
MOVING FORWARD AND WORKING TOGETHER
We have learned that we have to invest in the younger 
generation of scientists by providing not only robust edu-
cation but opportunities for post-graduate research and 
employment. We have also learned that it is essential to 
organize surveillance systems with ministries of health 
and veterinary services, as well as to help laboratory net-
works to communicate more efficiently on i) actions in 
the field, ii) training actions, and iii) establishing an easy, 
fair and transparent way of sharing samples and data 
during outbreaks. 
We know that infectious disease outbreaks are inevitable 
and recognize there are many obstacles to effective man-
agement and response when they occur. We believe that 
improving actions across these four areas is essential to 
being better prepared for and able to respond more effec-
tively, and that it takes a global community to do so. The 
IPIN is committed to working in partnership with multi-
sectorial partners, including the WHO, OIE, the Food 
and Agricultural Organization, academic, research, pub-
lic health and industry partners to achieve these major 
challenges of our era.  
H
ere, I outline three major areas of action that will 
help prepare for infectious disease outbreaks and 
what the Institut Pasteur International Network 
(IPIN), composed of 33 research institutes in 26 countries 
and five continents, is doing to address these issues.
ACTION NEEDED – BETTER PREPAREDNESS 
AND COORDINATION DURING PUBLIC HEALTH 
EMERGENCIES
Changes in ecosystems, due to changes in human beha 
vior and encroachment on the natural habitat of animals, 
changes in land use and food and agriculture systems, 
and the impact of climate change on animal and vector 
environments have given rise to an apparent increase in 
the number of outbreaks of emerging and re-emerging 
infectious diseases, often in somewhat new and unex-
pected geographic locations – H1N1pdm09 influenza 
virus in North America, Ebola in West Africa, and the 
Zika virus in Latin America and the Caribbean. 
The reality is that infectious disease outbreaks will con-
tinue to occur and we are currently unable to accurately 
predict when and where they will occur. The challenge 
therefore lies in improving preparedness and responses 
to infectious disease outbreaks in order to minimize 
their impact. That is, improving surveillance and moni-
toring of not only human populations, but also animal 
populations and the surrounding ecosystem, in order to 
be able to quickly detect, monitor and characterize 
emerging threats. This needs to be accompanied by rapid 
evaluations of the potential impact of an outbreak and of 
the effectiveness of possible control strategies. It is also 
urgent to further develop, improve and/or render acces-
sible relevant and diagnostic tools, including rapid tests, 
point-of-care tests and tests enabling us to discriminate 
easily among different pathogens often giving rise to 
similar syndromes.
The IPIN institutes have proven their technical capacities 
in preparing for and responding to infectious disease 
outbreaks with a One Health approach. As I write this, 
scientists of IPIN in Dakar, French Guiana, Brazil, Gua-
deloupe and Paris are actively working in the affected 
countries with WHO and others on Zika to develop 
accurate and rapid molecular and serologic diagnostic 
tests and vaccines, evaluate vector competence and 
control options, develop and implement standardized 
epidemiologic studies to better understand the diseases 
Zika causes in adults and fetuses of infected mothers as 
well as the transmission dynamics. Similarly, colleagues 
from Cambodia, Cameroon and Paris are actively inves-
tigating outbreaks of H5N1 in poultry, while others from 
Dakar and Paris are on the front lines of the yellow fever 
outbreaks in Africa.  
On the preparedness side, IPIN is active in 30 African 
countries to improve laboratory detection and effective 
surveillance, with training of African scientists and pub-
lic health workers as a major component. International 
collaborative projects have provided support to train 
African scientists for the detection of hemorrhagic fever 
viruses in eight countries, as well as to set up surveillance 
systems for respiratory viruses. 
Recent outbreaks of Ebola, Zika and yellow fever have high- 
lighted vulnerabilities and weaknesses in the way the global health 
community responds to these threats. The Institut Pasteur Inter-
national Network is working, with other international partners, 
toward improving preparedness and response to infectious disease 
outbreaks and proposes the following actions to address these 
issues. 
EBOLA TO ZIKA: 
AREAS OF ACTION
Author
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Improving access to healthcare in fragile environments of  
conflict, displacement and disaster is an urgent global challenge 
that goes far beyond the simple humanitarian imperative  
and demands concerted action on numerous levels. 
H
ealth care – in all its many aspects – is a major 
casualty of war and other situations of violence in 
many parts of the world today. Constrained access 
to emergency and basic healthcare services just when 
they are needed the most is one of the main problems fac-
ing many millions of conflict-affected people, and one of 
the main concerns of humanitarian organizations such as 
the International Committee of the Red Cross (ICRC).
Direct attacks on healthcare facilities and ambulances, 
which kill or wound staff and patients, are one part of the 
problem. The airstrike on the ICRC and MSF-supported 
Al Quds hospital in Aleppo, Syria, in April 2016 is just 
one example. It killed at least 49 civilians and six staff 
members, including one of the last paediatricians in the 
city, and destroyed vital equipment and drugs – an 
immeasurable loss to the many people for whom the 
hospital was a lifeline. In Syria alone, 63 MSF-supported 
hospitals and clinics were bombed or shelled on 94 sepa-
rate occasions in 2015, destroying 12 facilities. And Syria 
is by no means singular: the ICRC documented almost 
2,400 attacks against healthcare (personnel, facilities, 
transport and patients), by a range of perpetrators, in 11 
countries over three years up to December 2014.
Beyond the impact of specific incidents, the general inse-
curity and disruption created by armed conflict or 
violence, while hard to measure, undoubtedly has a mas-
sive impact on the provision of, and access to, impar tial 
healthcare. Even where healthcare facilities are function-
ing, albeit barely, reaching them may be fraught with 
dangers – and fear. Obstacles and threats directed by 
states and by non-state armed groups at health workers 
and humanitarian organizations that are seen to help “the 
other side” impede access for entire communities in need 
of vital medical care. Furthermore, the crippling loss of 
health professionals has compounded the humanitarian 
crises in countries like Syria, Iraq, Yemen and many oth-
ers. More than half of Syria’s doctors are reported to have 
fled or been killed (in opposition-held parts of Aleppo 
the toll is as high as 95%). 
Moreover, the generally protracted nature of armed 
conflict and armed violence, which is increasingly 
concentrated in urban areas, is in many cases causing the 
collapse of healthcare systems, together with other vital 
infrastructure and public services, reversing development 
gains previously made. The inability of such weakened 
systems to absorb new shocks – even years after conflicts 
have ended – was made painfully clear during the Ebola 
pandemic, chiefly in Liberia, Sierra Leone and Guinea. 
With healthcare systems largely incapacitated and coping 
mechanisms overstretched, millions of already vulnera-
ble people were at potential risk.
In armed conflicts, as in pandemics such as Ebola, vast 
numbers of people suffer and die not only from the direct 
effects but also because they are unable to access medical 
care for diseases or illnesses that could otherwise be treat-
ed or prevented altogether. 
Women and children are impacted the most. More than 
half of preventable maternal deaths and deaths among 
children under five occur in fragile settings of conflict, 
displacement and natural disasters. Worldwide, women 
and children are up to 14 times more likely than men to 
die in a disaster. And in an alarming number of cases, 
women and girls are deliberately targeted as a tactic of 
warfare, subjected to horrific sexual violence and other 
injury, with grave consequences for their psychological 
and physical health.
In Syria, as in many other countries suffering armed con-
flict, women lack access to appropriate healthcare ser-
vices during pregnancy and childbirth, either because 
they are unavailable or because it is too dangerous or dif-
ficult to reach them. As a result, many women are giving 
birth without any medical assistance – presenting huge 
health risks to mothers and babies. 
Infants who survive the early days after birth are in 
many cases exposed to further health risks because of 
the disruption of routine immunization programs. In 
Syria, polio has made a comeback after being eradicated 
in the 1990s, as well as deadly diseases like measles and 
meningitis. 
Women and children were also disproportionately 
impacted by the Ebola crisis. Barriers to access and weak-
ness of health systems – exacerbated by years of armed 
conflict and insecurity in the three worst affected coun-
tries – meant that maternal and reproductive health 
services were fragile even before the outbreak, making 
maternal mortality rates among the highest in the world. 
Pregnancy was shown to make women even more vulner-
able to the disease, yet in many cases health workers 
afraid of becoming infected refused to deliver post-natal 
and delivery care. Furthermore, as healthcare resources 
became ever scarcer, diseases such as malaria, HIV/AIDS 
and tuberculosis were in many cases left untreated, 
claiming yet more lives.
Meeting the massive and complex challenge of 
constrained access to healthcare in armed conflicts or 
other emergencies requires action on multiple levels by a 
range of stakeholders. One of the main problems in 
armed conflicts is a widespread lack of respect for the 
rules of international humanitarian law (IHL) by states 
and non-state armed groups, specifically the rules 
related to the protected status of the medical mission, 
and those governing humanitarian access to populations 
in need. Violence against healthcare facilities and 
personnel is clearly illegal under international law, while 
the wounded and sick – combatants and civilians alike – 
must be spared further suffering during armed conflict 
and receive timely assistance. In situations of violence 
other than armed conflict, international human rights 
law stipulates that states must refrain from deliberately 
withholding or delaying healthcare to the wounded and 
sick in life-threatening circumstances, and that everyone 
has the right to access essential healthcare facilities and 
services on a non-discriminatory basis.
The real challenge is preventing violations from happen-
ing in the first place. While primary responsibility for this 
issue lies with states and with combatants, national 
legislators and courts must also fulfil their responsibilities 
of ensuring that domestic legislation recognizes the crim-
inal responsibility of those who violate IHL, and of actu-
ally enforcing such legislation. Perpetrators of violations 
must be held accountable. The performance and behavior 
of humanitarian organizations and healthcare workers 
themselves is also critical. Securing acceptance for their 
work from all communities and political and military 
groups is essential to being able to work in sensitive and 
volatile contexts. This requires a clear demonstration of 
impartiality: the provision of healthcare based exclusively 
on humanitarian needs.
In countries where health systems are already fragile and 
access to healthcare is constrained under normal circum-
stances, sudden crises – such as the Ebola pandemic – can 
be devastating. The need for long-term investment at 
national and international levels to reinforce basic public 
health systems before disaster strikes is imperative. The 
most vulnerable should be prioritized, with maternal and 
infant health at the top of the list.
The Ebola outbreak also put into sharp relief the need to 
better boost the resilience of communities affected by 
multiple crises, as well as the need for humanitarian orga-
nizations – including the ICRC – to better anticipate and 
prepare for such crises.
Universal access to healthcare is a fundamental prerequi-
site to ensuring health and well-being for all, as aspired to 
by the Sustainable Development Goals. Achieving this 
will require innovative thinking, bold new approaches, 
and a major concerted effort across sectors. For the ICRC, 
this means better collaborating and co-creating innova-
tive solutions with increasingly diverse stakeholders – 
including certain states, the private sector, civil society 
organizations, academic and policy centers and many 
more. Partnerships, as well as principles and prepared-
ness, are absolutely vital.  
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even if you make a neutralizing antibody response, three 
weeks later or three months later this is not worth any-
thing because the virus or parasite has shifted its shape. 
We don’t know these things about Zika. So far, from the 
viruses to which that virus seems to compare, it would be 
a surprise if the virus were so variable. It’s a reasonable 
guess a vaccine is possible, but the evidence isn’t there. 
Turn the clock back two or three years to the virus of the 
moment. Back then it was Ebola. What’s the status of the 
science there? 
Very easy. You know, if it’s not a serious health problem then 
nobody cares. This was certainly the case with Ebola. Ebola 
had been known for quite some time, but never recognized 
as a big problem. And once an infection like this starts, there 
are always two types of measurements to deal with it. One is 
the purely hygiene prevention-type of measurements, 
which was the big problem with Ebola. Then come all the 
rest like looking for protective drugs and vaccines. 
What’s the evolutionary strategy of a virus like Ebola that 
kills everybody in five days? 
A virus that did that would be too successful. It would kill 
itself. But that never happens. Both sides have to find a 
balance, which we call co-evolution. 
Does that happen in the case of Ebola, for example? That’s 
something that springs from another species, potentially, 
and hasn’t had time to co-evolve.
In the 14th century, smallpox came from the east to con-
tinental Europe. Smallpox is about as lethal as Ebola. In 
some cities, 90% of the population was killed in the first 
round. The reason for that is the virus is very cytopathic: 
It kills many cells of the host and the host dies. But even 
smallpox never killed all Europeans, and the reason is 
very simple – the infection needs a certain population 
density to spread. Therefore it’s no wonder that smallpox, 
and also Ebola, really got off the ground in urban areas.
Even in the 14th century, smallpox hit areas where 
the population density was very low and very few people 
actually got infected. So there are many aspects that regu-
late the aggressiveness of the infection, like the popula-
tion density and culture.
“ We simply don,t  
 know enough”
Rolf Zinkernagel is Professor Emeritus of Immunology at the University 
of Zurich. In 1996, he was awarded the Nobel Prize in Medicine for  
his research into the way the body’s immune system recognizes cells 
infected with viruses. The discovery advanced clinical efforts to 
strengthen the immune response against invading microbes and 
certain cancers. It also aided in research on autoimmune reactions that 
cause diseases like multiple sclerosis and diabetes.
What has the international community learned about in-
fection from Zika, and what are the differences in terms 
of detection and the potential for a vaccine compared to 
Ebola? 
Zinkernagel — The difference is very simple – Ebola kills 
you in five to seven days. One is the acute, lethal type. 
Lots of classical infections belong to that category – mea-
sles, polio, smallpox, bacterial tetanus, diphtheria, and so 
on. If you don’t survive these infections you are out of the 
evolutionary circuit: All these diseases hit you before 
puberty. If you don’t have a good immune response 
against these acutely lethal types, you’re dead.
There are many more infections that do not harm 
the cells in which they grow. If a cell is infected with a 
virus that doesn’t destroy the cell, there is no clinical sign. 
In effect, it isn’t there as far as the immune system is con-
cerned. Examples of that type are hepatitis B, hepatitis C 
and HIV.
Many of these viruses are transferred from the 
mother to the newborn at a time when the immune sys-
tem doesn't work. There’s no immune response, and the 
offspring doesn’t die: It survives at least 30 or 40 years. 
The infected person will eventually develop liver cancer 
because of the infection, but that doesn’t interfere with 
reproduction. And in biology, that’s all that counts.
We don’t quite know whether the Zika belongs to 
that second category. After all, it hangs around for a long 
time, it doesn’t kill the mother, it doesn’t kill the offspring, 
and it seems to jump from mother to the offspring.
What about before birth? Because the changes from Zika 
affect fetal development in the womb.
We just don’t know enough at the moment. There are 
very, very few viruses that interfere with developmental 
processes. It’s actually a field that is almost unexplored. 
Do we know enough for you to be able to say something 
about the vaccine potential for Zika? 
No. We simply don’t know enough. What is important is if 
it is neutralizing antibodies. There are some indications 
that this might be the case, and then it should be reason-
ably possible. What we don’t know yet is how variable Zika 
virus is. Take influenza – the influenza virus changes the 
key protective surface deterrents every year or two. Other 
viruses – and all parasites, not just HIV or malaria – 
change these key protective deterrents every few weeks. So 
“ Viruses depend on our 
unreasonable behavior to 
spread, and we are only 
too happy to provide that 
to them.”
So there’s sort of a perfect match between them? 
Eventually. The same Ebola in a rural, spread out area 
wouldn’t have impacted people as heavily as it did in the 
urban areas. However – and now comes the but – 
hygiene, education or social structure can play a role too. 
That was the case or is the case in these parts of the world 
where family members and friends hug the dying person, 
which is an ideal occasion for Ebola to transfer.
So what would you say we can learn from these two cases? 
I think that ultimately there is nothing new. Acute lethal 
infections, which we by experience called childhood infec-
tions, need to be controlled, and the most efficient way to do 
that is by vaccines and hygienic measures. It’s very simple.
Then there are all the infections that don’t kill you 
in seven days but kill you in 20 years. Those basically are 
very difficult to control because the immune system can-
not normally deal with them. Once you’re infected and 
you’re a carrier of the virus, you cannot make a post- 
infection vaccine to get rid of the virus. Zika is a little 
different: So far we haven’t had to deal with an infectious 
agent that has a direct impact on fetus or embryo devel-
opment, so that is new. 
Is Zika comparable to herpes? In other words, you could 
be infected and get over it, but still be a carrier and al-
ways compromised in terms of whether you might pass it 
on to your offspring.
With all the herpes viruses, you usually get infected when 
you’re young. You control the infection but you never get 
completely rid of the virus. There’s a very low-grade 
infection somewhere. Herpes viruses are always persistent 
in nerve cells and don’t seem to interfere with functioning 
of the cells, which we just don’t know yet with Zika. 
Are we paying enough attention to Zika? Is it too much? 
How big of a problem is this really, and are we responding 
appropriately? 
I think that’s too difficult a question for me. We need sim-
ple epidemiology of the classical type: When does it hap-
pen? Where does it happen? How is it transmitted? When 
is transmitted? Where does the virus hide? When does an 
infected mother transfer to the offspring? Is it during a 
certain phase of the mother’s infection or can it happen 
once and then she’s infected all the time? These are all 
simple questions, but so far we don’t know the answers. 
So what do we do until then? 
Whenever they have the opportunity, humans like to be-
have stupidly. Viruses depend on our unreasonable be-
havior to spread, and we are only too happy to provide 
that to them. Most infectious diseases basically depend 
on unreasonable behavior of humans, including Ebola. 
Zika would not be a problem if, you know, people prac-
ticed safe sex and mosquito control – things that we have 
now been advocating for years.  
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HEALTH IN NUMBERS
Infectious Diseases:  
Lessons Learned  
from Ebola to Zika
MAIN DISEASES
STATEMENT
In the wake of the Ebola epidemic in Africa, the WHO has declared a global public 
health emergency based on clustered conditions thought to be caused by the Zika 
virus. The headline-grabbing viruses highlight a global threat from infectious 
diseases that are estimated to cost US $30 – $50 billion each year. Research on 
infectious diseases from AIDS and tuberculosis to Ebola must be combined with 






countries and territories have reported 
evidence of mosquito-borne 
Zika virus transmission since 2015. 
infected 10.4 million people in 2015 and killed 1.8 million. Over 95% of TB deaths occur in 
low- and middle-income countries. Asia, for example, accounts for 61% of new cases,  
followed by Africa with 26%. 
In 2015, there were major outbreaks 
of dengue fever worldwide, with 
the Philippines reporting more than 
169,000 cases and Malaysia an 
excess of 111,000 suspected  cases, 
a 59.5% and 16% increase in case 
numbers over the previous year, 
respectively. 
Since 1976, 6,023 people have died 
from the Ebola virus in Africa,  
75% of which were in West Africa 
in 2014 alone.
“The big three,” namely 
AIDS, malaria and  
tuberculosis, cause 
nearly 33% of all infec-
tious disease deaths. 
The world’s deadliest animal? The mosquito passes on diseases 
that kill approximately 725,000 people each year.
A lot of forces I ascribe  
to the Anthropocene 
are creating a whole  
new set of issues related  
to the expanding  
portfolio of infectious  
diseases.
(WHO, 2016)
(Centers for Disease Control and Prevention, 2015)
(Max Planck Institute, 2016)
Prof. Dr. Peter J. Hotez (President of the 







have been trained  
in infection prevention 
and control in West 
 Africa since the out-
break in 2014.
(Centers for Disease Control and 
Prevention, 2015) (WHO, 2016)
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T
he World Health Summit’s 
international character was 
striking. The three-day event 
brought over 1,600 participants from 
more than 80 countries to historic 
halls of the German Foreign Minis-
try. The Summit was also available via 
live-stream, and about 3,000 people 
tuned in and joined the active debate 
on social media. The global interest 
was a hopeful sign that a top goal of 
everyone there – namely, breaking 
down the silos that prevent the 
insights of one discipline from being 
applied to others – was within reach.
The Summit featured addresses by 
leading experts in global health, fun-
damental research, public and 
private policy. At the opening cere-
mony on Sunday afternoon, German 
Federal Minister of Health Hermann 
Gröhe called for cooperation: “Due 
to war and instability, we are facing 
an unprecedented influx of migra-
tion. Securing healthcare for refu-
gees is becoming an increasingly 
difficult challenge,” Gröhe said. “Suc-
cess can only be attained by joint and 
coordinated efforts.”
His speech was followed by remarks 
of Alain Berset, Federal Councillor 
and Head of the Federal Department 
of Home Affairs in Switzerland, and 
Ren Minghui, WHO Assistant 
Director-General for HIV/AIDS, 
Tuberculosis, Malaria and Neglected 
Tropical Diseases. Emmanuelle 
Charpentier, Director of the Max 
Planck Institute for Infection Biology 
in Berlin, then spoke strongly in fa-
vor of fundamental research. The 
French microbiologist reminded the 
audience that regulations can put sci-
ence – and national science programs 
– at a disadvantage. “CRISPR/Cas9 is 
a good example of how some coun-
tries can react faster than others,” 
Charpentier said. “In some coun-
tries, the train has already left the 
station, while in others, they’re still 
discussing the design of the train.”
The sessions that followed touched 
on issues including antimicrobial 
resistance, polio eradication, addic-
tion and cardiovascular health. 
University College London resear- 
cher David Napier explained the 
importance of culture in health and 
infant mortality, stem cell research 
and access to medicine in Africa. 
Dario Campana of Singapore’s 
National University Cancer Institute 
urged patience when it comes to see-
ing benefits from basic research. 
And Paul Hudson, CEO of Novartis 
Pharmaceuticals, emphasized indus-
try’s role in transforming how 
healthcare is delivered. “All of the 
conditions are here for us to do the 
right thing,” he said, “and for 
pharma to play its part.”
The role of entrepreneurs was 
highlighted by the World Health 
Summit Startup Track, a competition 
that brought ten finalists to present 
their ideas in front of a jury and the 
Summit’s expert audience.
Audiences at the Summit were 
diverse, both in terms of geography 
and age. Nobel Prize laureates and a 
class of curious high schoolers from 
the US passed each other in the halls, 
students from international public 
health programs pressed senior 
scientists on their findings and 
policy recommendations, high-rank-
ing representatives of civil society 
and the private sector shared tables 
during sessions and breaks alike.
One of the Summit’s key topics this 
year was the role of women, a theme 
that was reinforced by a panel 
discussion on “Women, Empower-
ment and Health” that closed the 
Summit. Fittingly, the Summit’s final 
day coincided with the International 
Day of the Girl.
The need for progress made by wom-
en in the public health sector was 
underlined by panelist Heidemarie 
Wieczorek-Zeul. Indeed, “There is 
no path to this goal if we do not 
empower women and girls,” 
Wieczo rek-Zeul said.
WHS Presidents Antoine Flahault 
and Detlev Ganten joined incoming 
WHS President Hélène Boisjoly on-
stage to read the M8 Alliance Decla-
ration – a call to action on points 
like guaranteeing refugees health-
care and urging governments to 
continue investing in research, 
development and innovation. “It’s 
not the closing ceremony, it’s the be-
ginning of a new era,” Ganten said. 
The entire M8 Alliance Declaration 
can be found beginning on page 65. 
Need for Progress
Technological innovation and women’s empowerment were  
in focus at the World Health Summit 2016 as hundreds  
of the world’s top public health thinkers gathered in Berlin.
World Health Summit - Berlin 2016
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World Health Summit — Berlin
“ The 2030 Agenda 
provides us with an 
incredible opportunity 
to accelerate the pro-
gress of public health. 




Assistant Director-General for HIV/AIDS, TB, 
Malaria and Neglected Tropical Diseases (WHO)





tion head  
Ann Aerts (1) 
addressed the 
impact of non- 
communicable 
diseases.  





made a case for 
basic research 
and WHS 









Sunday, October 9, 2016
10:30 AM
Workshop 
Ending the AIDS Epidemic
Room Adenauer 
“The modern paradox is the fact that 
what is haunting our society more 
than the epidemic is the stigma 
associated with being gay or an 
intravenous drug user,” said Luiz 
Loures, Deputy Executive Director of 







“Ebola is a peace and wartime  disease. 
Now is the peace time – and we need 
to be preparing for war,” said Stefan 
Kaufmann, Director of the Max Planck 
Institute for Infection Biology. “It’s 
more expensive to deal with the 





“The involvement of non-governmental 
organizations is indispensable for solving 
global health problems,” said German 
Minister of Health Hermann Gröhe.
“An unwavering commitment to solutions 
and perspective is important when 
isolationist voices are threatening to 
divide us,” emphasizes Erwin Böttinger, 
CEO of the Berlin Institute of Health.
WHO’s Ren 




Minister of Health 
Hermann Gröhe, 
Alain Berset of 
the Swiss Federal 
Council and 
Erwin Böttinger, 
CEO of the Berlin 
Institute of 
Health, met at 
the Summit (3). 
















Director of the 
Institute 
of Pathology 
at the Charité 
(6, left), speaks 
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Monday, October 10, 2016
“ If you are a refugee, 
you are more  
likely to face physical 
and mental  
health risks that 
could destroy  
your future.”
HELLE THORNING-SCHMIDT 
CEO of Save the Children 
International
Helle Thorning- 






The Weltsaal was 
packed (2) 
during major 
panels on topics 
like technological 
innovation (3), 
After a long  
day of talks 
participants 
gathered at the 
WHS Night to 
network and 




As a student I feel like you 
can absorb so much here. It 
is a great chance to find 
new ideas and actually 
pursue them, to understand 
what you want to do in  
the field of public health.
LIANA PETROSOVA
Maastricht University,  
Netherlands
If you want to learn about 
what is really going on in 
healthcare you come to the 
WHS. This year they have  
hit the nail on the head: 
planet health, antibiotic 
resistance, migration and 
health, SDGs – I think these 
topics are going to be there 
with us for the next 10 years. 
DR. BOGOSI MOGALE
Embassy of the Republic of South 
Africa, Belgium
I went to a session on 
government for health. I had 
not thought of corruption  
as a transparency issue 
before. It is a sensitive topic; 
it was nice to hear people 
speak so openly about it.  
LEILA YOUSIF
Management Center Innsbruck 
(MCI), Austria 
Here you can feel solidarity 
amongst different stake- 
holders in public health and 
the desire to share 
knowledge. We are all here 
to make something happen.
OCHE ITODO
EHESP School of Public Health, 
France
Here I have learned how 
health is approached from a 
global perspective, with a 
focus on containing 
outbreaks and managing 
migration. It is very 
different from Cambodia, 
where we worry most about 
weak governance. 
SEAN TSI
National University of Singapore, 
Singapore
What brought me here were 
the topics and meeting the 
community. I was familiar 
with the concept of “value 
and health” but at the 
session they developed it so 
much further.  
ANNIKA CALOV




Coalition for Epidemic Preparedness 
Innovations (CEPI) 
Room Adenauer
“We don’t know which country will be 
hit by the next epidemic. The only 
way to make sure we have the right 
resources to meet those challenges is 
to co-invest,” said John-Arne Rottingen, 
Director of the Division of Infectious 
Disease Control at the Norwegian 





“There are two types of tuberculosis: 
active and latent,” said Sanofi Aventis 
Vice-President for Access to Medi-
cines Robert Sebbag. “In case of 
climate change, or decreasing humidity, 
you can change from latent to active 




Technological Innovation for Health 
Weltsaal
“By 2020, it is estimated that 80% of the 
adults on the planet will have access to 
a smartphone,” said Stanford University 
School of Medicine Dean Lloyd B. Minor. 
”That is going to change the way people 
get information about their health, and 
give us data so we can better under-






patron of the event,” explained 
Minister Gröhe in his speech. Short-
ly after, Elad Fein, CEO of iFeel 
Healthy, emphasized just how 
important this opportunity is: “We 
want to help the hundreds of mil-
lions of people that have respiratory 
problems in a fun way.” Key to 
reaching those people is reaching a 
global audience, which is one of the 
reasons why iFeel Healthy applied 
to the WHS Startup Track 2016.
Other startups echoed the sentiment. 
“The World Health Summit is the 
collection of all the pieces of the puz-
zle in global health,” said Joshua 
Okello, the CEO and co-founder of 
Uganda-based startup WinSenga. 
“That is why we came here.” WinSen-
ga is a portable ultrasound device. It 
connects to a smartphone and allows 
midwives in resource-poor regions 
to monitor fetuses. Okello des- 
cribed it as a modern update on the 
Pinard horn, a low-tech 19th century 
listening device, for those who can-
not afford another alternative. 
Symptoma, an Austrian startup, also 
proposes a high-tech solution to an 
age-old problem. Healthcare profes-
sionals can enter different symptoms 
and lab results into the platform, 
then the software weighs the differ-
ent possibilities to produce a diag-
nostic report. “Experts once deemed 
something like this impossible,” said 
Symptoma CEO Dr. Jama Nateqi. 
Today, the technology has caught up. 
“Now we are showing that it is possi-
ble and that medical misdiagnoses 
are a problem worth trying to solve.”
An all-in-one blood sampling device 
that integrates blood collection with 
testing and analytics was pitched by 
midge medical UG from Germany. 
Using a smartphone as a bar code 
scanner, it can also connect to a 
database that helps healthcare work-
ers manage patients. Michael Die-
bold, the firm’s CTO, said the device 
– which is simple, easy to use and 
does not need power – was particu-
larly practical in rural environments 
and emergency situations where 
electricity was hard to come by or 
intermittently available. Each midge 
testing pod even comes with its own 
disinfectant wipe.
Other startups included Care Across, 
a network connecting cancer pa-
tients and their caregivers with med-
ical experts within hours; evivecare, 
a speech therapy app for stroke pa-
tients; Glasschair, a Google Glass app 
that drives a wheelchair with head 
movement; OneWorldDoctors, a 
platform that connects doctors and 
specialists to improve medical infra-
structure in underserved regions; 
Pelvifly, which attempts to help mil-
lions of women who have issues with 
incontinence due to age or pregnan-
cy complications. Finally, Germany’s 
Cold Plasmatech is seeking ways to 
harness the power of cold plasma 
for dermatological and antibacterial 
applications.  
WHS Startup Track
Tech Takes the Stage 
WHS Startup Track 
The World Health Summit Startup Track draws attention to the roles business 
and entrepreneurship have in improving the global healthcare system.
A
t the World Health Summit 
2016, technology was a hot 
topic. To help small compa-
nies and startups compete against 
well-established players, the WHS 
Startup Track – now in its second 
year – invited young entrepreneurs 
to present  concepts for healthcare 
of the future in a competitive pitch 
session in front of a jury and 
audience. 
This year, 10 ambitious innovators 
took the stage in the Europasaal. The 
general focus was on new smart de-
vices, software and applications. In a 
sense, they were already winners: The 
startups represented some of the most 
outstanding healthcare business ideas 
garnered from a pool of 80 proposals 
from 22 countries. Each participant 
made a three-minute pitch and 
addressed questions from the jury. 
Later that day, German Federal Min-
ister of Health Hermann Gröhe, 
patron of the WHS Startup Track, 
announced the WHS Startup Track 
Winner: iFeel Healthy from Israel. 
“The Startup Track offers young 
companies from all over the world a 
unique opportunity to network with 
each other and make important 
contacts, That’s why I took over as 
“How can a mobile game that you 
love help you with asthma?” Elad 
Fein asked the jury and audience 
at the WHS Startup Track this 
year. Fein, who is the CEO of iFeel 
Labs, won the WHS Startup Track 
2016 competition with the iFeel 
Healthy app. 
iFeel Healthy monitors and ana-
lyzes respiratory function using 
popular mobile games with a small 
wearable device. It also helps man-
age maladaptation to stress. Users 
are trained to breathe properly and 
strengthen their lungs. If the data 
from the pulse oximeter in the 
wearable senses that the heart rate 
and breath are not in sync, the 
game is locked. The user has to 
breathe properly in order to unlock 
the game and continue playing. 
Over 300 million people suffer 
from asthma worldwide. When 
presenting the award at the WHS 
Night, German Federal Minister 
of Health Hermann Gröhe said the 
startup was a “revolutionary ap-
proach to one of the biggest global 
health problems today.” 
iFeel Healthy is an example of 
medical insights paired with tech-
nological innovations. But the 
transition is difficult. Reaching 
the right audience, such as the 
governments and institutions 
present at the World Health Sum-
mit, is important: “Winning the 
WHS Startup Track 2016 could 
push us forward and help make 
digital health available to a large 






The WHS Startup Track put 10 busi-
nesses from Austria, Greece, Germa-
ny, Israel, Poland and Uganda in front 
of an expert jury and audience to 
present their ideas (3). 
German Minister of Health Hermann 
Gröhe (1) announced the Startup Track 
winner iFeel Healthy, an asthma-treat-
ment app, at the WHS Night. Urszula 
Wójtowicz (2) represented Pelvifly, one 
of 10 startups competing.
Elad Fein pitched his iFeel Healthy 
app to a jury of experts.
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At home in Berlin.
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“To prevent cardiovascaluar disease, the 
first step is to make sure that everyone 
knows their own blood pressure, even 
children. The material is cheap, it is easy 
to handle – people just have to have 
access and know how to use it. We have 
to bridge this knowledge gap,” said 






“A lot of healthcare is delivered by 
communities. That’s an opportunity – 
fewer or no sunk costs, no existing 
infrastructure and less divided 
public opinion puts us in a position 
to leapfrog old technology,” said 
Norbert Hauser, Chair of the Board 




Implementing the Health-Related SDGs
Room Rathenau
 
“Academic institutions and think tanks 
should take their models to the 
ground. They should not wait for 
countries to shop around. They should 
work in countries directly to imple-
ment them,” said Joy Phumaphi, 
Executive Secretary of the African 
Leaders Malaria Alliance.
“ Women constitute an 
army of unpaid  
care providers and 
the highest propor-
tion of paid health-
care  professionals. 
Healthy women  
are so important.”
MATSHIDISO REBECCA MOETI






Karen Linehan (1,  
left and right), 
Nobel laureate 
Elizabeth Black-
burn (3) and 
Afghan Ambas-
sador Suraya 









and Paul Hudson 
(5, from left) 
discussed the 
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T
his year’s World Health Sum-
mit (WHS) took place in a po-
litical context of great hope 
and serious alarm. Immense strides 
were made to strengthen commit-
ments to the Sustainable Develop-
ment Goals and to global health ac-
tion at the UN General Assembly, the 
World Health Assembly of the WHO, 
as well as at G7 and G20 meetings. 
The right of all people to universal 
health coverage (UHC) has been em-
phatically endorsed. But at the same 
time, the plight of millions of people 
on the move, the predicament of ref-
ugees and the unacceptable destruc-
tion of health facilities clearly showed 
the limits of humanitarian and global 
health action when there is a lack of 
political will to ensure human rights, 
peace and security.
The past year has reinforced that we 
must face global health challenges 
collectively: the challenge of antimi-
crobial resistance has been likened to 
climate change; the Ebola crisis has 
been followed by severe Zika and 
yellow fever outbreaks; and there is 
increasing concern that the target of 
polio eradication might not be 
reached on time.
Crises are a key determinant of 
health – be they war, insecurity, eco-
logical or financial upheaval. Around 
the world, 130 million people need 
humanitarian aid, more than 60 mil-
lion people have been forcibly dis-
placed from their homes, the global 
migration and refugee movement 
shows no sign of abating and many 
countries are still burdened with the 
health consequences of austerity. A 
new mix of health inequity, humani-
tarian, ecological and security chal-
lenges has emerged which confronts 
us with the limits of existing systems. 
Donor countries are stretched to 
keep their global commitments as 
pressure increases at home to set new 
priorities and cut development aid. 
Terrorist attacks all around the world 
have increased a general feeling of 
insecurity and have led to protec-
tionist responses. This raises basic 
questions about global solidarity in a 
world of great wealth.
We, the members of the M8 Alliance, 
call on heads of state and govern-
ment to invest in people and to en-
sure that no one is left behind. Fol-
lowing the discussion at this year’s 
World Health Summit, action in five 
key central areas of global health is 
mandatory:
1. Empowerment of Women and 
Girls
2. Right to Health of Refugees and 
Migrants
3. Resilience and Global Health 
Security
4. Antimicrobial Resistance
5. Investment in Research, Develop-
ment and Health Innovation
I. EMPOWERMENT OF WOMEN 
AND GIRLS
Achieving progress in global health 
requires addressing the health, edu-
cation and empowerment of women 
and girls. Indeed, advancing gender 
equality creates measurably healthier 
and more productive communities 
and could add US $12 trillion to 
global GDP by 2025. Supporting all 
women, especially the most margin-
alized, in reaching their full potential 
at every stage of life is a priority. This 
includes equal access to healthcare, 
sexual health and rights, enhancing 
reproductive health, improving in-
fectious and chronic disease protec-
tion and treatment, and addressing 
aging issues. It also requires applying 
a gender lens to all health issues. 
Call for Action: 
The M8 Alliance calls for supporting 
policies which increase women’s 
control of their life choices and en-
sure their bodily integrity. This in-
cludes the right of women to modern 
family planning and safe abortion. 
We recognize that progress has been 
achieved for women over the past 
decades, but in many countries the 
reality on the ground continues to 
fall short. The main determinants of 
women’s health are not being ad-
dressed appropriately by govern-
ments. We are particularly con-
cerned about the ongoing epidemic 
of gender-based violence. We also 
call for a greater recognition of the 
contribution of women as paid and 
unpaid health workers and see a clear 
need to address the global care chain 
in the context of health worker mi-
gration.
II. RIGHT TO HEALTH OF 
REFUGEES AND MIGRANTS
Global health still fails the most vul-
nerable: populations in fragile states, 
victims of war, refugees, asylum 
seekers, trafficked populations, peo-
ple in forced labor, slaves and global 
migrant workers. Refugees and mi-
grants have the same universal hu-
man rights and fundamental free-
doms, including the right to health. 
Our approaches to global health 
must integrate people’s movements 
as a key determinant of health and 
we must develop strategies that can 
respond to the diversity of people on 
the move, as well as their needs. 
The M8 Alliance Declaration 
World Health Summit 2016
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M8 Alliance Declaration
Call for Action: 
The M8 Alliance calls for a welcoming 
of the outcome of the first UN Sum-
mit on large movements of refugees 
and migrants in 2016, which guaran-
teed the safety, dignity, human rights 
and fundamental freedoms of all mi-
grants and reinforced the legal frame-
works for refugees. The response 
framework that has been developed 
will guide further action, also in 
health. It reinforced that everyone has 
the right under international law to 
the highest standards of physical and 
mental health. It has also highlighted 
the need for equity and access. We un-
derline the need to monitor the fol-
low-up to these commitments and to 
ensure the full accountability of UN 
organizations, humanitarian actors 
and nation states.
III. RESILIENCE AND GLOBAL 
HEALTH SECURITY
Significant activity to improve pre-
vention, detection and response time 
to outbreaks has been underway 
around the world following the Ebo-
la crisis. We welcome the many ac-
tions and initiatives to build health 
resilience, including the new WHO 
Health Emergencies Programme, the 
Global Health Security Agenda, the 
launching of the Pandemic Emer-
gency Financing Facility, and the 
support for the Ebola-affected coun-
tries in building their health systems. 
The continuing concern of the G7, 
the G20 and the UN will be critical to 
establish a global system of pre-
paredness and response and secure 
sustainable financing for work on 
health crisis and to invest in UHC. 
This includes ongoing attention to 
other public health emergencies of 
international concern (PHEIC) such 
as polio and Zika. 
Call for Action: 
The M8 Alliance calls on all coun-
tries and development partners to 
ensure the full implementation of the 
International Health Regulations 
(IHR) capacities. We encourage all 
countries to engage in tabletop and 
simulation exercises to test gaps in 
capacity and to do this in full coop-
eration with many sectors. Health 
systems must be strengthened, pro-
fessionals trained and communities 
fully involved. Mechanisms for 
accountability to the global commu-
nity – through reliable, independent 
and external evaluations – must be 
established. This includes the com-
mitment to ensure the last phase of 
polio eradication and the transition 




At the UN General Assembly this 
year, the heads of state and govern-
ment acknowledged that the resis-
tance of bacterial, viral, parasitic and 
fungal microorganisms to antimi-
crobial medicines is the greatest and 
most urgent global risk, requiring 
increased attention and coherence at 
the international, national regional 
levels. Following the recommenda-
tions of the WHO, they have called 
for a global development and stew-
ardship framework which brings to-
gether the many stakeholders – from 
health and agriculture to food, ani-
mal health, development banks, and 
UN agencies – to address the enor-
mous challenge to humankind. The 
M8 Alliance will work hard to imple-
ment a multi-stakeholder approach 
in the development of national, 
regional and global alliances and 
strategies to address antimicrobial 
resistance (AMR). 
Call for Action: 
The M8 Alliance calls for an endorse-
ment of the political declaration on 
AMR and the WHO action plan on 
AMR. In particular, we support re-
search and development of new anti-
microbial medicines, vaccines and 
diagnostics. We further call for de-
termined action on implementing 
the One Health approach to fight 
AMR and we reinforce the need to 
ensure access and affordability. All 
healthcare institutions and profes-
sions must do their utmost to fight 
AMR.
V. INVESTMENT IN RESEARCH, 
DEVELOPMENT AND HEALTH 
INNOVATION
We must harness the enormous po-
tential of science to better meet ur-
gent global health needs. A stronger 
focus on translational research can 
help turn early-stage innovations 
into new health products, advancing 
innovation to the point where it be-
comes attractive for further develop-
ment by the medical industry or 
healthcare agencies. Many new dis-
coveries have the potential to im-
prove health, but turning those ideas 
into deliverable products can prove 
extremely difficult. We require a 
stronger focus on the cooperation 
between public and private sector 
and between basic scientists, clinical 
researchers, clinicians and patients 
to drive novel observations about the 
nature and progression of disease 
that often stimulate basic investiga-
tions. This requires new incentives, 
innovative funding streams and new 
solutions to challenges in relation to 
intellectual property, as has been 
outlined in the report of the UNSG 
High Level Panel on Access to Medi-
cines issued this September 2016.
Call for Action: 
The M8 Alliance calls for cross-sec-
toral contribution to developing strat-
egies in translational research, secur-
ing the translation of results from 
clinical studies into everyday clinical 
practice and health decision-making, 
while ensuring that new treatments 
and research knowledge actually reach 
the patients or populations for whom 
they are intended. We also commit to 
ensuring patients’ participation in 
such developments. The M8 Alliance 
will promote the effective translation 
of new knowledge, mechanisms and 
techniques generated by advances in 
basic science research into new ap-
proaches for prevention, diagnosis 
and treatment of disease, so that the 
essential goal of improving health 
from bench to bedside can be reached. 
We understand that this will require 
new forms of cooperation between the 
public and the private sector.
The M8 Alliance emphasizes that the 
challenges facing global health have 
become too numerous and too com-
plex for a business-as-usual ap-
proach. We will continue to do our 
utmost to engage actors at all levels 
and from all sectors to move this 
agenda forward.  
http://bit.ly/M8-Declaration_2016 www.pfizer.com
Before it became 
a medicine,
It was 5,OOO researched compounds.
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36 clinical trials.
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Before it became a medicine,
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Now it’s a medicine
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Technological  
Innovation 
By 2020, 4.6 billion people will own a mobile 
phone. The opportunities for improving healthcare 
are tremendous: Technology makes it possible to 
communicate better with patients and collect data 
that deepen our knowledge of disease.
But there are threats, too. Deep-seated distrust of 
technology is widespread, along with fears that  
big data will lead to “Big Brother”-like abuses of 
personal information.
As technological advancement races ahead, can 
public health keep up? And equally importantly, is 
it possible to distribute technology’s benefits  
evenly? “Global health needs to push for afford-
able, sustainable innovation,” said Antoine  
Flahault, Director of the Institute of Global Health 
at the University of Geneva, at the WHS Opening 
Ceremony. “It needs to work in a framework  
of human rights and dignity.”
WORLD HEALTH SUMMITYEARBOOK 2016 7170
Technological Innovation
Digitization, data and connectivity are changing the way the world 
works. Today, virtually every industry – from publishing to  
agriculture, from aerospace to travel – is being profoundly disrupted. 
Y
et, compared to progress in other industries, 
healthcare is still just in the infancy of a data- 
driven revolution. Digitization offers a golden 
opportunity to tackle our biggest health challenges in a 
move towards outcome-based care delivery. Further still, 
it could enable unprecedented improvements to care 
access, particularly to those in resource-limited settings.
To put the challenge we face in context: Populations are 
aging and chronic conditions continue their relentless 
rise. Health systems are creaking under the pressure. 
Meanwhile, the industry tends to work in silos optimized 
around medical specialties rather than the patient. This, 
in turn, results in high levels of waste and misdirected 
resources. Misdiagnosis is just one stark example. For 
cancer care, the figure stands at 20-30%, depending on 
which survey you read.
It is little wonder that most resources go to episodic acute 
care or that cross-workflow collaboration is scarce, as op-
posed to efforts being directed towards addressing socie-
tal trends, root causes or striving for integrated solutions. 
While healthcare remains a somewhat conservative and 
regulated industry, we are seeing digitization and connec-
tivity, through big data, unlock insights for deep and 
far-reaching industry transformation. 
One immediate challenge is how we manage this transi-
tion to digital health effectively and efficiently. In mature 
health systems, vast amounts of data input fields remain 
“analog” and have yet to be digitized. Incremental 
increases in digital health technologies will, of course, 
bring even greater data proliferation and more connected 
measurable insights. In emerging markets, this challenge 
becomes an opportunity. In places where legacy infra-
structures are not so embedded, we can achieve a 
“leapfrog” moment in health transformation in a 
straight-to-digital approach. 
In both scenarios, long-term thinking and a solutions-ori-
entated approach are required to manage digital transfor-
mation and unlock the potential of connected health. 
For large-scale transformation, one clear trend is the 
“industrialization” of care. The principle is simple: break 
down any complex process into its constituent parts and, 
once you’ve digitized, you can stitch together each compo-
nent seamlessly online. That’s how great online retailers or 
logistics providers make a complex service feel joined-up 
and efficient. For healthcare, the concept is a gem! 
Industrialization is also driving systematic improvements 
in care delivery – supporting the move from reactive 
acute care to proactive chronic disease management and 
stimulating greater patient and clinical investment in life-
styles and prevention. Further still, precision medicine, 
the delivery of precise and first-time-right diagnosis, is 
now an emerging reality thanks to new smart diagnostic 
technologies and better connectivity across the health 
continuum.
The cloud plays a huge role here, which leads to the next 
trend: the “personalization” of care.
The proliferation of smartphones and other connected 
devices means that consumer and professional healthcare 
is converging. Increased patient, and consumer, empow-
erment is one immediate outcome – allowing patients to 
remain informed, proactive and have more choice in their 
own health and medical well-being. Further still, when 
harnessed well, individualized treatment plans can be in-
formed by connecting multiple data points.
There is tremendous value in how we build, scale and 
analyze patient profiles. By harnessing and processing a 
diverse range of individual patient data across the full 
spectrum of care, we can apply a deeper understanding of 
wider population trends. As such, big data and analytics 
are forging impactful population health management 
solutions that offer real opportunities to reduce the cost 
of care and ease pressures on overburdened health 
systems. 
When coupled with “tele-health” or remote monitoring 
solutions that connect population patterns with real-time 
patient-data, the potential is tremendous, especially when 
it comes to reaching less engaged patients in resource-lim-
ited or deprived areas. This is where population health 
delivers highest impact by increasing patient health liter-
acy and engagement, and in addition, providing critical 
access that is all too often absent – all without placing a 
heavy burden on primary care. 
This is not a substitute for face-to-face care. But, by main-
taining a continuously-connected relationship with high-
risk patients remotely, care providers can identify indi-
vidual and population health issues and formulate 
combined prevention and treatment strategies.
One compelling example is in Liverpool, UK. Philips 
partnered with the NHS to deliver a large-scale self-sup-
ported care pilot targeting chronic disease management 
for patients in the city’s most impoverished areas. Over 
three years, 2,234 patients with one or multiple chronic 
diseases including COPD, heart failure and diabetes were 
enrolled. The program combined tele-monitoring equip-
ment in the home with the support of a clinical hub and a 
structured program for case management, monitoring, 
education and coaching.
By engaging patients using a full array of connected 
technologies, the program achieved reductions in emer-
gency admissions and secondary care costs ranging 
from 22 to 32%. Ninety percent of patients felt more in 
control, have gained confidence and / or felt better able 
to cope with their condition. Again, this is another 
 example of connected care improving lives and saving 
essential resources. 
Finally, the need for inclusive innovation and design is 
also key to how we manage healthcare transformation. 
This means breaking out of silos in order to tackle 
structural constraints that contribute to poor health 
alongside primary care needs building a holistic view of 
universal healthcare in a dual approach to improved care 
delivery and access. 
The value in this approach is immediately clear in emerg-
ing markets. For example, Philips Community Life Cen-
ters are transforming primary and community-based 
care in rural Africa. The self-sufficient centers house 
state-of-the-art primary care health and IT facilities for 
diagnosis, testing, treatment and training. 
While simultaneously acting as mother and child centers 
to address urgent infant mortality rates, additional value 
is achieved through the provision of 24/7 sustainable 
light, power and clean water. This allows the centers to 
function far beyond the core primary care focus and act 
as safe and secure sites for community engagement with 
added communal energy and sanitation resources. Inclu-
sive innovation in this way has embedded the long-term 
building blocks of improved universal health within the 
communities they serve, while also dramatically expand-
ing primary care capacity. 
Ultimately, if we are to fully capitalize on the potential of 
digitization and connected care, we require a different 
end-to-end approach in how we define and manage 
healthcare systems, with better outcomes, lower waste 
and variance. We are only scratching the surface of the 
potential. Technological innovation for robust and high 
quality data insights is necessary. But, most important is 
getting the processes right so that what we’re connecting 
is transparent and logical – changing consumer, patient 
and clinical behaviors to adapt to new ways of working.
Deep collaboration and co-creation with partners will 
also enable us to further develop high impact consultative 
solutions. This means sharing joint responsibility for out-
come-based metrics like improved efficiency, higher 
quality, reduced costs and, ultimately, better patient 
health outcomes with customers and partners.
This is progressive work, and it is very promising. But 
we have much to do to make integrated digital health a 
reality.   
Author
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Technology – whether mobile, online or device-based – has  
revolutionized our daily lives. Its role in global health is that of a 
strategic enabler and sustainable change-maker, dependent  
on its complex relationships with individuals and health systems. 
The benefits of integrating? Priceless. 
T
he five horsemen of technology are nanotechnolo-
gy, biotechnology, information communication 
and technologies (ICT), robotics and applied cog-
nitive science. Together, they have changed daily life for 
billions around the world. Over 3.6 billion people in the 
world own a mobile phone, a number the global mobile 
phone association, GSMA, estimates will reach 4.6 billion 
by 2020. In the world of international development and 
global health, that amounts to simple mathematics: 4.6 
billion unique mobile phone subscribers equals 4.6 bil-
lion opportunities for global health to create a 
game-changing and sustainable change. 
Mobile money, another game-changer, has revolutionized 
the way businesses operate and individuals make and re-
ceive payments. More than 400 million registered mobile 
money connections are present in the world today. 
TECHNOLOGICAL INNOVATION MUST RELY ON 
COMPLEX RELATIONSHIPS
Integrating technological changes and innovative 
platforms with healthcare delivery is not without its own 
challenges – and yet, it is necessary. Take a generic health-
care patient pathway in India, and we see at least seven 
relationships to work through: the individual seeking 
treatment, community healthcare workers, health clinics, 
laboratories, pharmacies, rural hospitals, and larger, refer-
ral hospitals. Add in partners like donors, ministries of 
health, drug manufacturers and regulators, and one is 
faced with myriad public and private healthcare systems 
that are disparate and at times, collaborating together. 
Once we add in technological innovations, the core ques-
tions become what elements should be prioritized, and 
what solutions need to be integrated? How has technolog-
ical innovation led to a more efficient, effective and im-
pactful system that provides the most benefit to the pa-
tient? 
Technology can also protect patients from counterfeit or 
“fake” drugs, whether it be by scanning products at each 
stage of the supply chain to confirm authenticity or by a 
patient using their mobile to scan or send codes to an au-
thentication service. Technology can also powerfully 
connect different approaches so that end-to-end security 
of a supply chain is achieved, ensuring that a medicine 
goes from factory to patient without issue. 
Technological innovation cannot be seen as a standalone 
solution – it is an enabler in complex connections, 
whether it is facilitating a relationship between a commu-
nity health worker and a patient through WhatsApp to 
provide educational awareness on malaria; creating a 
relationship between a health clinic and a “rider” provid-
ing ARV medicines through riding his bicycle; or build-
ing a relationship of trust as a patient agrees to use 
biometric technology for improving tuberculosis treat-
ment as is done by Operation Asha in India. 
DONORS FUNDING TECHNOLOGICAL  
INNOVATION FOR GLOBAL HEALTH
Technological innovation is becoming a core part of 
health ecosystems across countries and at a global level, 
with donors and funders supporting innovations. We wit-
ness a growth of innovation labs and testing platforms. 
The US Agency for International Development’s (US-
AID) Global Development Lab, Unicef ’s Innovation Labs 
and the Gates Foundation’s investments in technology are 
a few such examples. 
The Global Fund to Fight AIDS, TB and Malaria, the 
world’s largest funding agency to fight the three diseases, 
remains on track to save over 22 million lives by the end 
of 2016. It realizes the immense impact technology can 
leverage by nature of its funding to more than a 100 coun-
tries. The Global Fund established the Innovation Hub in 
2014 as a partnership engagement platform focused on 
solutions in three key areas: procurement and supply 
chain management, financial and risk management, and 
program quality. As of 2016, the Innovation Hub leads 
over 30 key relationships, each of which has been identi-
fied and tested for maximum impact.
THE GLOBAL FUND’S ROLE IN ACCELERATING 
TECHNOLOGICAL PLATFORMS TO STRENGTHEN 
HEALTH SYSTEMS
Through the Innovation Hub, the Global Fund worked 
with PharmAccess Foundation and Vodafone in Kenya to 
develop a mobile health wallet, called M-Tiba, using 
M-Pesa as the backbone. This allows someone visiting a 
clinic for a malaria test to pay for it from their mobile 
phone and allows the clinic software to collect age, gender 
and test results – in turn providing powerful potential for 
use of data. M-Tiba stands out as an innovative platform 
to tackle numerous health challenges through one solu-
tion: addressing quality of care and turning real-time data 
into targeted health services. In Kenya, the Global Fund’s 
principal recipient, AMREF, now uses M-Pesa to pay sal-
aries and related payments through the health chain. This 
simple solution has helped incentivize health workers by 
paying on time, reducing the risk of carrying cash and 
tracking payments. Beyond M-Pesa, the Global Fund is 
also partnering with Vodafone Group to deploy inven- 
tory platforms in selected countries. Relaying data on 
mobile, the platforms are aimed at preventing medicine 
shortages at the regional stores and health center level.
In addition to supporting last-mile delivery and strength-
ening health system supply chain management, techno-
logical solutions and devices have a critical role in the 
future of eliminating AIDS, tuberculosis and malaria in 
the coming decades by ensuring that early detection of 
diseases such as malaria and HIV/AIDS can help save an 
even greater number of lives. The GeneXpert test, 
endorsed by the WHO just over five years ago, is a new 
molecular test that detects the DNA in TB bacteria and 
gives results in less than two hours. In Nigeria, the bio-
tech innovation of using a urine test for malaria results in 
diagnoses in less than 25 minutes. And the Boston-based 
Disease Diagnostic Group’s Rapid Assessment of Malaria 
(RAM) – is a mechanical device that promises to detect 
malaria in only five seconds using a drop of blood. Simi-
larly, self-testing kits for HIV are currently being piloted 
in Zimbabwe, Malawi, Zambia and South Africa.
WAMBO.ORG: THE GLOBAL FUND’S ONLINE 
MARKETPLACE TO POOL PROCUREMENT
The Global Fund has developed a new online marketplace 
that gives countries the tools to access pooled procure-
ment which helps reduce the price of products. Wambo.
org is a simplified procurement platform, requiring only 
an Internet connection, and it provides implementing 
partners the power to search, compare, purchase and 
track the delivery of transparently priced, quality-assured 
medicines and products. 
The Global Fund is also a founding member of the Global 
Steering Committee for Quality Assurance of Health 
Products and Services (GSC) to advance coordinated 
action against counterfeit health products that endanger 
public health. Members include Gavi, United Nations 
Development Programme (UNDP), UNITAID, US 
Agency for International Development (USAID), US 
Food and Drug Administration (FDA) and the World 
Bank. They work closely with the private sector to coordi-
nate and amplify activities to strengthen regulatory 
systems, increase awareness and build and connect 
reliable data. 
In addition, the Global Fund supports the Global Health 
Assurance Partnership (GHAP) which conducts market 
assurance reviews and, if necessary, helps the country 
solve any issues. 
PARTNERSHIPS ARE KEY TO HEALTHCARE 
DELIVERY
Technology is rapidly advancing and here to stay. Whether 
it is mhealth platforms in Asia, mobile money in Africa, 
robotic ATM-like pharmacies in South Africa, or un-
manned aerial drug delivery in Rwanda, the future of 
healthcare delivery is fast evolving and changing. The key 
to long-term sustainable strengthening of healthcare 
delivery can only lie in partnerships ensuring that 
donors, countries, private sector partners, and communi-
ties that we serve work together to find the most effective 
systems for their needs.  
Author
NORBERT HAUSER
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Harnessing the power of big data offers a way forward for health-
care on a massive scale, while holding out the promise of solutions 
that are effective because they are tailored to individual patients. 
But to get there, researchers and practitioners will have to break 
down silos and win the trust of patients and doctors.
P
recision Health, the global approach to healthcare 
that we are championing at Stanford, has its roots in 
the teachings of Hippocrates. The fundamentals of 
this approach – individualized care that’s predictive, pre-
ventive, and specific – were trumpeted by the ancient 
Greek physician when he said: “It is more important to 
know what sort of person has a disease than to know what 
sort of disease a person has.”
Jump forward a few millennia, and, for the first time in 
history, we find ourselves in possession of the transfor-
mative technology and other tools needed to bring the 
vision for truly personal healthcare to life. Precision 
Health involves the precise application of science across 
the spectrum to predict and prevent disease before it 
strikes, and cure it decisively if it does. It uses all possible 
data points – genetics, environment, behavior, and socio-
economics – to provide care that’s not one size fits all, but 
one size fits one. 
While most medical research is currently focused on ge-
netics and medical treatment, evidence shows that paying 
close attention to all four of these data points is key to 
achieving optimal health. In the 1990s, for instance, Los 
Angeles was one of the most polluted cities in the world. 
Now, two decades later, the air is significantly cleaner. A 
study of this 20-year period by the University of Southern 
California demonstrated that lung function had 
improved in local children: In 1998, 8% of 15 year-olds 
had significant lung defects; by 2011, that number had 
fallen to 3.5%.
From a global health perspective, consider the case of 
clean drinking water. The World Health Organization 
(WHO) estimates that 2.3 billion people gained access to 
improved drinking water between 1990 and 2012. During 
this same time, the number of children dying of diarrheal 
diseases, strongly correlated with a lack of access to clean 
water, steadily fell. 
And in a behavior-related example, Stanford Medicine 
epidemiologist Sanjay Basu analyzed a recent change in 
the payment schedule of Peru’s cash assistance program: 
The government moved from twice-monthly to 
once-monthly payments, without changing the overall 
payment amount. Under the new schedule, he observed a 
striking increase in the purchase of “temptation goods” – 
alcohol, sweets and tobacco – that have a negative impact 
on health. The Peruvian government once again makes its 
payments every two weeks as a result.
At Stanford Medicine, we’re putting Precision Health into 
action across every area that influences health. Just one 
among many real-world uses is our MyHeart Counts app, 
developed in partnership with Apple, that taps the 
iPhone’s built-in motion sensors to both monitor an indi-
vidual’s own cardiovascular health and share that heart 
and activity data with researchers at Stanford. Data from 
the MyHeart Counts study are used to help ordinary peo-
ple manage their risk of heart disease.
Now is the moment for individuals and practitioners 
alike to embrace the extraordinary potential of Precision 
Health – and to surmount the four top hazards that could 
prevent us from fully realizing what is the most important 
healthcare goal in generations.
Silos are among the hazards, dominating much of the 
current medical and scientific research in Precision 
Health areas. Without question, researchers in these areas 
need to work together to thoroughly grasp the unique 
health status of each individual – and they need to engage 
in extended collaborations across institutions and indus-
tries. We’re already seeing glimmers of this in things like 
the Stanford Woods Institute for the Environment, which 
is partnering with over 25 groups to explore our effect on 
the environment and its effect on us, as well as the new 
US $250 million Parker Institute for Cancer Immuno-
therapy, comprised of six of our country’s leading can-
cer-fighting institutions that are tackling the disease 
through a team approach. Success requires more of this 
cross-pollination.
Speed of progress is another obstacle – counterintuitive, 
yet real. Medical knowledge has advanced so far and fast 
that a majority of practicing physicians actually went to 
medical school before the human genome was sequenced. 
The repercussions of this were captured in a recent 
Genetics in Medicine survey, showing that many doctors 
worry about misunderstanding genetic test results or 
conveying them incorrectly. We need to ensure that all 
doctors, old and new, are proficient in understanding 
genetic tests of diagnosis (and predisposition) to disease, 
and to develop efficient and effective ways to make sure 
medical knowledge is readily accessible.
Privacy concerns also continue to loom large in the minds 
of patients. We can hardly blame them: One cyber- 
security think tank this year estimated that 47% of 
Americans had had their medical records hacked in the 
past twelve months. We must solve the issue thoroughly 
and systemically, while encouraging individuals to share 
their information with programs and institutions that are 
committed to data security. Precision Health won’t keep 
individuals healthy without data, and we must develop 
the secure technologies and rigorous procedures to 
assuage patient fears. 
While currently a roadblock, cost will not always be. De-
tractors of the more precise approach say individual 
genetic sequencing tests (a pipe dream a decade ago) are 
too pricey. True, these tests can cost thousands of dollars, 
which insurance companies may now be reluctant to pay. 
Developing targeted drugs with their associated diag- 
nostic tests isn’t cheap, either. But costs will decrease as 
technology progresses. We’ve seen it before – take MRIs. 
We can help history along by maintaining our focus on 
reducing costs whenever and wherever possible. More-
over, prescribing drugs and other treatments based upon 
information on which patients will benefit, rather than 
using the same approach for everyone, will decrease the 
cost to the healthcare system overall. 
 
“Experimental audacity that was unimaginable in the 
past” – this was Stanford Medicine professor Paul Berg’s 
phrase for the dawn of recombinant DNA in the 1970s, 
which led us to the brink of today’s biomedical revolution 
in Precision Health.
Berg laid the groundwork for this revolution with his 
Stanford peer, Stanley Cohen, when they mixed DNA 
from different species to engineer new genes and ushered 
in the molecular biology boom. Cohen and University of 
California San Francisco Professor Herb Boyer then used 
that technology to produce the first therapeutic proteins 
for humans. They patented gene cloning in 1974. This led 
to, among other things, the founding of Genentech.
Years later, Genentech developed the first real example of 
precision medicine, tailoring medical treatment to the in-
dividual characteristics of the patient – Herceptin for 
HER2+ breast cancer. We’re now going beyond the spec-
tacular promise of precision medicine to true Precision 
Health – with its focus not just on effective treatment, but 
on prediction and prevention.  
Author
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Lack of real-time access to data and meaningful insights is slowing 
innovation in healthcare. Being patient-centric, providing  
transparency, and leveraging the power of ecosystems will lead  
to fundamental change.
T
Technology has clearly transformed much of what 
we do in our daily lives: how we manage our financ-
es, how we consume news and entertainment, how 
we shop. But when it comes to a central part of our lives 
– our health – digital transformation has lagged behind.
While we’ve seen encouraging movement toward the dig-
itization of records and significant advancements in the 
area of data analytics, much of the data remains discon-
nected, siloed and opaque. Digitizing health information, 
while necessary, is not sufficient. Real transformation will 
only happen when information is connected, integrated 
and delivered in real-time.
The lack of progress toward the digital age in healthcare is 
driven by a number of factors, including a regulatory 
environment that does not fully understand or embrace 
the benefits of technology, competing interests across 
healthcare stakeholders, and initiatives that are not cen-
tered around the patient. However, today’s healthcare 
industry is at a tipping point. The same pressures that 
have propelled change in other industries are driving the 
need for new solutions in healthcare: rising costs and the 
pursuit of value. Citizens, governments and businesses 
are more aware and more concerned about increasing 
costs. Individuals and families are more focused on 
healthcare quality. Patients have more choices and 
demand a better experience. 
To transform the healthcare industry, we need to take 
lessons from other consumer services that start with the 
user at the center and deliver amazing experiences by 
creating open systems or “platforms” that connect and 
leverage the power of others.  
I propose three core lessons that are most relevant to our 
work in healthcare innovation:
 ȣ Start with the consumer – the patient 
 ȣ Offer transparency and insight by connecting 
the enormous amounts of data we have 
 ȣ Leverage the power of an ecosystem; i.e., the 
power of others 
First, we must start with the consumer. Solutions need to 
be personalized and have complete, real-time medical 
data. They must give patients control over how and with 
whom information is shared and for how long. And, they 
need to work on the user’s behalf. Knowing the person 
and the context of their request, applications should de-
liver the desired result, with minimal input from the pa-
tient or healthcare provider. 
Second, we need to provide transparency into the massive 
amounts of available health and healthcare data, connect-
ing silos and giving access to the right stakeholders. We 
can bring together structured and unstructured clinical 
data, claims data, genomic data, and data from wearables, 
as well as operational and financial data from healthcare 
organizations. Then, we can make the data accessible and 
meaningful to different stakeholders across the ecosys-
tem, with the patient’s permission.
For research communities, we can increase the sample 
size significantly to use the power of large numbers to 
garner better, more useful, more accurate insights. We 
can enable powerful, new correlations and predictions – a 
major benefit that a more limited view can’t offer. We can 
also use data insights to improve the value-to-cost ratio in 
healthcare, research and life sciences organizations. 
Finally, we need to leverage the power of others. Today’s 
most pervasive technologies are those that have effective-
ly built ecosystems around a platform. The innovation of 
individual companies can often be inspiring, but it’s noth-
ing compared to the innovation of communities. Think, 
for example, about the iPhone. It is a beautiful product, 
but it is the community of partners that surrounds it that 
makes the phone indispensable.  
To enable this community, we need to build open plat-
forms, breaking down barriers and working together to 
foster openness and partnerships. When we collaborate, 
we can radically improve the experience and value for 
those we serve.
I believe we can do these three things within healthcare. 
We can leverage the power of networks to create solutions 
that are built around the user and turn data into transpar-
ency and insights and, in so doing, fundamentally change 
healthcare as we know it.
This year in the United States alone, about 1.7 million 
people will be diagnosed with some form of cancer, but 
only about 5% of these patients will participate in clinical 
trials. Data on the other 95% of patients is secured in 
disjointed electronic health records across physician 
practices and hospitals. In 2015, SAP partnered with 
CancerLinQ, a non-profit subsidiary of the American 
Society of Clinical Oncology. CancerLinQ is a health 
information technology platform that aggregates and 
analyzes the rapidly-growing store of patient data to 
uncover insights and trends and to benchmark physi-
cians’ care against current recommended guidelines. 
CancerLinQ amasses structured and unstructured data 
from disparate electronic health record systems, unlock-
ing data silos by de-identifying and aggregating patient 
data from across the United States, revealing patterns and 
insights that will lead to improved, more individualized 
patient care from personalized insights. CancerLinQ will 
offer anonymized data to researchers and pharmaceutical 
companies for targeted cancer treatment advancements. 
CancerLinQ runs on SAP Connected Health built on 
SAP HANA, an in-memory data management and appli-
cation platform. CancerLinQ’s data lake currently has 
more than one million patient records, and more than 
1,500 physicians from 70 practices have signed up to 
participate. CancerLinQ allows physicians to view and 
compare patients’ treatment plans to see how peers are 
treating similar patients, and identifies opportunities in 
their own patient population to deliver timely, recom-
mended care following appropriate guidelines. 
In closing, I ask three things of all of us. First, let’s work to 
update regulations to support – not constrain – data 
sharing. Let’s look at what policies need to shift, what bar-
riers can be lifted, and what progress we can make 
toward a more open and collaborative ecosystem. 
Second, let’s be willing to share our data and our innova-
tions. Consider whether we have data that would be 
useful to share, how we can foster a culture of openness 
and sharing in our organizations, and whether there’s an 
app or solution we’re building that would benefit from a 
collaborative community. 
And finally, let’s embrace new types of partnerships, seek-
ing out ways to partner with other organizations across 
the ecosystem to help spark new ideas and new ways to 
address important issues in health. The advancements we 
seek will only come from collaboration and working 
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27% saying: “yes, I use healthcare technology for moni-
toring my health,” 95% would like to pass this on to 
future generations.
So they’re open to it? 
Absolutely. In addition, we can identify those people who 
do not use it themselves but are still open to change. 
Taken together, we see little evidence that people reject 
the idea of using technology in the future.  
However, there is serious concern that the develop-
ments will be in such a direction that people cannot and 
do not want to adopt. These are the boundaries of accep-
tance that I mentioned before. People recommend 
advancement to a certain extent but they expect develop-
ments to go beyond. This is viewed as a future role of 
healthcare technology that they do not want to accept or 
would recommend accepting. 
Were you surprised about the initial openness?
Most people recommend to future generations exactly 
what they themselves are doing. This willingness to go 
with technological change surprised me.
The second surprise was that people who are disad-
vantaged are the ones who are actually in favor of this 
improved health technology. We usually assume it’s 
society’s more privileged people who use all the newest 
technologies. This is in fact not what we found. That is 
good news. People with a poor education and low income 
“ People indicate that they 
would like to change”
Jutta Allmendinger is president of the WZB Berlin Social Science Center and 
former director of the Institute of Employment Research in Nuremberg. A 
sociologist, her specialty is the impact of institutions on the life course. She 
has served on national advisory committees for research and innovation  
 and anti-discrimination. In cooperation with the research institute infas and the 
German weekly DIE ZEIT, she recently conducted a large, nationally represen-
tative survey of popular attitudes towards key aspects of life, including work, 
family, nutrition and technology. Among the topics addressed in particular  
was healthcare technology. 
You’ve just completed a huge study asking three thousand 
citizens between the ages of 14 and 80 about their under-
standing and acceptance of healthcare technology. What 
were the most important lessons you learned? Is the basic 
idea that people who trust technology now think they will 
in the future as well?
Allmendinger:  — The basic question is to what extent 
people accept improvements in healthcare technology. 
We can say that about half are adamantly opposed to ge-
netic diagnostics and individual health monitoring. 
Those are impressively low numbers.
Low compared to other countries? 
No, low in absolute terms. Many technological innova-
tions have the potential to keep people healthy longer, but 
first people have to use them. For that to happen, we need 
to have basic acceptance. That’s at the core of preventive 
medicine.
To measure basic acceptance, the use of new 
technologies is one indicator. The potential use of new 
technologies is another. Therefore, we have not only 
asked “What kinds of healthcare technology do you 
use?” but also whether people would recommend using 
these technologies to future generations. Moreover, the 
boundaries of acceptance are important to identify. So, 
we asked: “What extent of use do people recommend, 
and what is over the top?” 
What we found is that people who actually use 
healthcare technology today are quite in favor of its use 
in the future, and would recommend it to others. Of the 
“ A lot of these techno-
logical innovations 
have the potential to 
keep people healthy 
longer, but first they 
have to use them.”
are much more likely to fall ill because of wrong lifestyle 
choices. It turns out they’re the ones who are most open 
to change. I hope that they will really do this and get the 
support they are going to need.
The third surprising fact is that people are moving 
forward somehow but are afraid of going all the way. They 
are really afraid of the future they expect. 
Could it be that poor people are more impressed by 
doctors? That they are more willing to trust the experts? 
I don’t think so. They are poor, they don’t think of them-
selves as having good job opportunities. Maybe many of 
them feel that heathcare is the last system that will pro-
vide the same opportunities for everyone – regardless of 
their income and social position, which do limit their 
chances in the educational system. 
Can these findings be applied to other countries? 
This is a Germany-specific survey, and although we have 
now been asked by Italy to replicate the study there, I 
don’t know the results yet. But we know that other coun-
tries are further along when it comes to thinking about 
healthcare technology. They are also more open to com-
munication technology and the Internet in general than 
are Germans. For historical reasons, Germans have seri-
ous problems with privacy rights connected to big data, 
which is one of the venues in which healthcare delivery is 
making enormous advancements. And they’re right, I 
guess. 
So what are the lessons for policymakers and doctors? 
The message is: We have to educate people and make 
them familiar with new technologies and how those 
new technologies can bring them better health over 
their entire life course. Simply put, there needs to be 
much more education on health than what we have at 
the moment.
The other lesson points in the opposite direction. 
Given the fact that some groups show initial acceptance, 
you have to reassure them that they can keep the right to 
opt out of or reject the use of those technologies. There’s a 
school of thought that believes if they give away personal 
or private data, corporations like health insurance com-
panies will be able to do whatever they wish to do with 
the data without asking. It’s suddenly turning into a ques-
tion of privacy rights. This can also be shown with our 
data: Over half of the respondents firmly reject the idea of 
giving data to insurance companies.
If you want to develop a national digital health system or 
improve things on a large scale, can some people opt out? 
Yes, I think that you need to give them that opportunity. 
Or else they won’t be willing to opt in in the first place. 
INTERVIEW
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Successful healthcare quality and delivery depends on the tools and devices used 
for prevention, diagnosis, treatment and rehabilitation. Technological  
innovations in the field are helping reduce inefficiencies in healthcare delivery 
while, at the same time, streamlining access, reducing costs, improving quality 
and making medicine more personalized and precise.
BIG DATA
BOOMING BUSINESS
The market for 
medical robots 
is expected to 
reach US $11.4 
billion by 2020, 
up from US $4.2 
billion in 2015 –  
a compound 
annual growth 




formation is lacking 
in healthcare.  
The data is analog, 
siloed and opaque. 
Transformation is 
driven by connection, 
and data needs 
to be integrated 
and real-time.
Due to rapidly increasing data 
volume and new technologies 
for data analytics, big data is a 
huge topic in medical circles. In 
Germany alone, revenue from 
big data analysis is expected to 
reach € 3.6 billion in 2016. 
2012 2013 2014 2015 2016(Bitkom, 2014)
(MarketsandMarkets, 2015)
Steve Singh (SAP SE President for Business 
Networks and Applications) at WHS 2016
3D PRINTING
MOBILE APPS
3D printing was born. Charles 
Hull invented the stereo- 
lithography, a printing process 
that enables a tangible  
3D object to be created from 
digital data. The technology 
is used to create a 3D model 
from a picture.
Less than 1/4 of all 
mHealth apps  
are about specific 
diseases, medica- 
tion reminders  
and healthcare  
providers.
With US $104 billion 
invested in the  health 
IT market, 2016 was 
one of the biggest 
years for healthcare 
technology ever. The 
worldwide health IT 
market is expected to 
















(Doctors without Borders, 2016) (MarketsandMarkets, 2015)
(IMS Institute for Healthcare  
Informatics, 2015)
NANOROBOTICS
(University of Montreal, 2016)
(International Journal of Multidisciplinary 
Research and Development, 2015)
A team from Doctors without 
Borders created 3D models  
and a virtual reality reproduction 
of a recently designed facility 
in the Philippines that was later 
built to help people after a  
2013 typhoon.
In 2016, researchers from the 
University of Montreal and McGill 
University developed new nano-
robotic agents capable of navigating 
through the bloodstream to deliver 
anti-cancer drugs directly to tumors.
PEAK
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The theme “Global Health: Sustain-
able and Affordable Innovation in 
Healthcare” palpably permeated the 
GHF 2016’s three days’ program. A 
special highlight for participants as 
well as media representatives was the 
“Tomorrow’s Affordable Hospital” 
exhibit. A small hospital was recon-
structed, allowing visitors to  discover 
several innovations at the individual 
stands. The inventions on display 
were selected according to two crite-
ria: their accessibility (i.e., afford-
ability for all) and their low environ-
mental impact (i.e., sustainability). 
The 300 square meter temporary 
hospital was organized into six 
departments: 
1. Internal medicine: addres-
sing public health issues. 
2. Gynaecology, obstetrics and 
neonatology: dealing with 
complications following 
childbirth. 
3. Laboratories and medical 
imaging: presenting inno-
vations inspired by the TV 
series CSI. 
4. Pharmaceuticals: focusing 
on counterfeit medicines 
and presenting a machine 
designed for rural hospitals 
to find out the composition 
of a drug and determine if it 
is genuine or a fake.
5. Logistics: tackling issues of 
water purification and pro-
tection against infections. 
6. Training and research: un-
veiling various telemedicine 
systems that allow doctors 
in rural hospitals to contact 
urban experts. 
Highlights included a pharmacy 
equipped to detect counterfeit drugs, 
a digital radiology unit customized 
for tropical climate conditions for a 
fraction of the market price, guid-
ance on how to wash your hands 
while only consuming 10 cubic cen-
timeters (or 10 milliliters) of water, 
and even a shower that used only a 
single liter of water. 
THE FEDERAL CAFÉ –  
A PLACE TO MEET
The Federal Café sessions offered an 
ideal spot for Swiss organizations 
and especially non-governmental 
organizations (NGOs) to introduce 
topics of special interest. Presenta-
tions included “Globalization of 
Clinical Trials,” “Mastering Health 
Data” and “Health Promotion.” Many 
participants eagerly used these ses-
sions to discuss new global health 
perspectives in an open debate while 
enjoying beverages and snacks. They 
established new communities and 
networks of shared interest with 
people from all around the world.
1,200 PARTICIPANTS FROM  
80 COUNTRIES
The GHF 2016 hosting the WHS 
Geneva Meeting proved to be a 
unique opportunity for collaboration 
between the academic and hospital 
world, policymakers, experts from 
major global health NGOs, pub-
lic-private partnerships, and repre-
sentatives of the private sector. On its 
tenth anniversary, the Geneva Health 
Forum attracted a record 1,200 par-
ticipants from 80 countries, showing 
that two internationally leading con-
ferences working together for the 
shared goal of improving health 
worldwide could be a tremendous 
success. 
As World Health Summit 2016 Pres-
ident Professor Antoine Flahault put 
it, “the 6th edition of the GHF host-
ing the World Health Summit de-
fined how we want to act on global 
health at Geneva. It demonstrated 
our deep commitment to ethics and 
values, from advocating against vio-
lence against women to debating the 
IT revolution’s impact on the health 
sector. The world we want must pro-
vide health innovations to all.”
The next Geneva Health Forum will 
be held in 2018. The next WHS 
Regional Meeting will be organized 
in May 2017 in Montreal, Canada. 
www.worldhealthsummit.org
www.ghf2016.g2hp.net
The WHS Regional Meeting 2016 was 
held in Geneva, Switzerland (1), where 
researchers gathered to debate impor-
tant issues (2). Antoine Geissbuhler 
gave an Innovation Award to Audrey 
Garcia (3). Didier Pittet, Mauro Poggia 
and Bertrand Levrat (4, from left) dis-
cussed healthcare policy.
Combined Conferences 
Break Records  
WHS Geneva Meeting 2016 
O
n the occasion of the Gene-
va Health Forum’s sixth 
edition and 10 year anni-
versary, the World Health Summit 
Regional Meeting 2016 was orga-
nized in Geneva and called the 
WHS Geneva Meeting. This part-
nership emphasized the deep 
friendship of these global networks, 
expressing the desire to mutually 
support each other on an interna-
tional level and across all sectors. 
Both the organizers and the more 
than 1,200 attendants in Geneva 
agreed that collaborations like this 
are pivotal to improve health on a 
global scale as agreed.
WORKSHOPS ESCAPE THE 
USUAL ROUTINE
After more than a year of prepara-
tions, the WHS Geneva Meeting pre-
sented eight specially marked ses-
sions organized by members of the 
M8 Alliance. The workshops dis-
cussed major global health issues like 
research funding, medical education, 
sustainability and affordability. 
Simultaneously, the Geneva Health 
Forum (GHF) organizers convened 
11 groups of experts from six conti-
nents to answer major questions on 
health issues. The goal was to address 
topics in depth in specially designed 
workshops, breaking away from the 
usual routine of many international 
conferences. The sessions tackled a 
wide range of topics, including ac-
cess to cancer treatment for children 
in the poorest countries, mental 
health in remote regions and tele-
medicine. These experts repeatedly 
met via teleconferences and in per-
son in a closed session on April 19 to 
refine their data and presentation. 
The findings and recommendations 
were presented in open parallel ses-
sions on April 20 and highlighted in 
the last plenary session on April 21. 
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In a society that prizes results and deliverables, 
the importance of basic research is sometimes 
overlooked. Yet from infectious disease treatments 
to cancer cures, the mechanisms of our biology 
must be understood before doctors can devise 
treatments.
While major breakthroughs in science sometimes 
take years of translational research to make the 
leap from bench to bedside, only continued 
investment in our understanding of basic biology 
can continue pushing medicine forward.
That’s a challenge public health professionals must 
be willing to tackle. “The system we have in most 
countries is one where science and care are largely 
disconnected,” Erwin Paul Böttinger, CEO of  
the Berlin Institute of Health, said at the WHS. 
“We need to bring science, research and clinical 
care together.”
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science and engineering technology to the clinic is one of 
the most pressing research and development issues 
worldwide. The path leading from knowledge about basic 
human biology and disease mechanisms to clinically 
applicable diagnostics, therapeutics and prevention mea-
sures presents a variety of hurdles and bottlenecks. These 
include communication and collaboration gaps, separate 
infrastructures, insufficient research time for clinicians, 
and lack of access to a wide range of data from both 
pre-clinical and clinical practices. More work is needed to 
support innovation and the creation of value. New educa-
tion and training programs will be essential to ensure that 
scientists and clinicians become the driving force behind 
translating today’s discoveries into health benefit.
In short, in a shifting healthcare landscape, translational 
medicine has become a global priority. In order to over-
come these challenges, foster the transformation towards 
a value-based, innovative and even more personalized 
medicine, and increase success rates, key issues have to be 
addressed. 
SOLUTIONS TO FOSTER INNOVATION IN 
TRANSLATIONAL MEDICINE
More than ever before, technology plays a significant role 
not just in supporting research, but also in driving key 
advancements in science and discovery.
Digitization: Digitization is transforming research and 
healthcare. The introduction of universal electronic 
health records and digital clinical information systems 
has helped revolutionize the quality of healthcare in some 
countries including, for example, the United States. Link-
ing clinical data with information from insurers, data on 
people’s fitness and even genome-level data allows clini-
cians to make informed decisions in real time and 
enhances the development of personalized medicine.
Patient involvement: Fostered by digitization develop-
ments, patients are increasingly taking on a more active 
role in the treatment of their own diseases and are thus 
contributing to research and healthcare. In the future, 
patients will become even more involved in helping 
researchers formulate important research questions, and 
will often benefit directly from the contribution of their 
personal data. This will lead to significant advances in 
clinical research approaches and methods.
Systems medicine research: New technologies in systems 
medicine research involving genetic, systems biological, 
clinical, environmental and behavioral data must be used 
to develop markers and models that characterize inter- 
individual differences better to improve diagnoses and 
risk predictions, particularly for distinct subgroups.
Advanced therapies: Stem cell technologies and gene- 
editing techniques are two of the most promising recent 
developments in biomedical science. The ability to re- 
program common cells, such as those in blood, and turn 
them into the multipurpose cells the body uses to regen-
erate tissue has already become a powerful treatment 
tool. And the use of enzymes to alter gene sequences, for 
example, by repairing disease-causing mutations, could 
soon be widespread. Both are valuable in developing 
personalized therapies. 
Innovation: The physical process of bringing new ideas 
and promising therapies to fruition is one of the toughest 
challenges in biomedical research, and one of the most 
important for a translational medicine center to do right. 
Researchers must know what to do with promising 
results, have a clear pathway to follow, and have expertise 
to support them in bringing a therapy to market. 
TRANSLATIONAL RESEARCH IN GERMANY
Coupled with advances in digital medicine and informa-
tion sciences, these innovative fields have created huge 
opportunities to develop new ways of tackling disease 
and advancing translational medicine. In Germany, six 
Centers for Health Research, launched by the German 
federal government in 2010, are addressing the challenge 
of translational research in common diseases. As inter-in-
stitutional centers with a decentralized structure, these 
centers pool knowledge and expertise from universities 
and their teaching hospitals plus extra-university institu-
tions. Berlin Institute of Health (BIH) is yet another 
translational research organization bundling strengths in 
one location and focusing on personalized medicine. The 
institute with its member entities (Charité – Universitäts-
medizin Berlin and Max Delbrück Center for Molecular 
Medicine in the Helmholtz Association) addresses the 
key solutions outlined above as part of the “BIH Strategy 
2026.” BIH aims to achieve scientific breakthroughs and 
ultimately develop tools that predict disease as well as 
therapies that save lives and prolong quality of life. And, 
BIH wants to achieve significant medical achievements 
with a truly integrative and interdisciplinary systems 
medicine approach, new alliances and research initiatives 
as well as an entrepreneurial culture of innovation. The 
ultimate objective: long-term, sustainable impact for 
humankind.  
 
While considerable progress has been made in advancing the 
 understanding of health and disease mechanisms, scientific 
 advances have not always resulted in direct benefits to patients. 
 Translation of biomedical ideas into societal and economic  
benefits that improve people’s quality of life is necessary.
T
he scale of the demographic challenges ahead, ris-
ing healthcare costs, the burden of progressive dis-
eases and their impact on our societies, on health-
care, and on research have all become familiar but are 
nonetheless significant. These developments will lead to 
far-reaching changes in patient care, biomedical research 
and the whole healthcare sector in this century. Future 
healthcare will be marked by a range of influential trends.
FACING POWERFUL CHALLENGES
Due to the rising average age of citizens in the industrial-
ized societies, there are an increasing number of people 
with chronic diseases. Thus, there will be more people at 
higher risk of needing care. Progressive diseases in par-
ticular lead to a reduced quality of life for sufferers and 
high treatment costs for healthcare providers. In response 
to these developments, within modern healthcare sys-
tems the reimbursement of healthcare services is increas-
ingly dependent on improved quality and quantifiable 
results. These value-based programs – for example, the 
Quality and Outcomes Framework in the United King-
dom – have, in the initial analysis, achieved better results 
at lower cost. On top of that, they have reduced socio- 
economic disparities in healthcare provision.
Another evolving challenge which will affect the health-
care system is a new paradigm of biomedical research. A 
better understanding of the underlying mechanisms and 
causes of diseases as well as technological advancements 
are transforming medicine from a reactive to a proactive 
and personalized discipline. Systems medicine approa- 
ches to biology and medicine provide patients and 
clinicians with personalized information about each 
individual’s unique health experience at the molecular, 
cellular and organ levels. This information will make dis-
ease care radically more cost-effective by personalizing 
care to each person’s unique biology and by treating the 
causes rather than the symptoms of disease. Systems 
medicine is a holistic approach to the challenge of biolog-
ical complexity. In order to yield a comprehensive under-
standing of human biology, it uses high throughput 
technologies – such as DNA and RNA sequencing – to 
produce global data sets tracking multiple dimensions of 
dynamic network interactions. With this information, 
scientists and clinicians can begin to understand how an 
individual’s genetic make-up and environment mutually 
influence health and disease. 
Above that, the digital revolution introduces radically 
enhanced capabilities for collecting, integrating, storing, 
analyzing and communicating data and information, 
including conventional medical histories, clinical tests 
and the results of the tools of systems medicine (e. g., bio-
informatics, data science). Also important is patients’ 
access to information and rising interest in “managing” 
their own health.
MOVING MEDICINE FORWARD FASTER 
However, these are not the only trends and challenges to 
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This strategy is anchored in our success, as shown by inter-
national evaluations of the main affiliated research units, in 
providing leading publications linking vision, neuro- 
science, healthy aging and neurodegeneration, cognitive 
sciences and neuroengineering in health and disease.
From a methodological point of view, we have consoli-
dated the ability to combine different modalities (as 
shown in our success performing simultaneous EEG/
fMRI studies to study cognition and mechanisms of dis-
ease such as in epilepsy). Finally, we have a research 
agreement with Siemens, which allowed for the first 
time to implement GABA measuring sequences in their 
scanners (and together with a collaboration with John 
Hopkins University a clinical neuroscience study). We 
have also implemented a novel data-mining biomedical 
facility with significant impact in the development of 
novel diagnostic tools and therapeutic targets. 
Internationalization is well grounded, with partnerships 
including Euro-BioImaging, the International European 
Consortium on Imaging Infrastructures, the Joint 
Program of Neurodegenerative Diseases (EU), European 
Networks, E-Rare European Initiatives (two consortia), 
as well as European projects with a focus on neuro- 
imaging and neuropsychiatric diseases (BrainTrain and 
Autism Consortia). 
Our strong radiopharmaceutical expertise is well substan-
tiated by our track record in molecular probe production 
and molecular imaging. We have unique expertise and the 
equipment for developing imaging markers in brain, heart 
and cancer imaging. ICNAS can run Phase 0 micro- 
dosing studies, and clinical imaging trials in humans. It 
also develops new imaging techniques in partnership with 
industry, and labels candidate drugs for scientific and 
industry studies. Aside from hosting the national core 
brain imaging network infrastructure, we began distribu-
tion of our own FDG formulation in 2012 and quickly be-
came the market leader, supplying 80% of the country’s 
active PET scanners in 2012. This provides tight coupling 
 between research and services to the community.
In sum, we cover a broad range of disciplines, which is 
well documented by the interdisciplinary nature of our 
staff. These include MDs, pharmacists, biomedical engi-
neers, psychologists, biologists and biochemists, each 
with a broad interest in complex biomedical data, clinical 
trial design and biomarker research.  
The Brain Imaging Network core infrastructure of Portugal hosted 
at the University of Coimbra’s Institute of Nuclear Sciences  
Applied to Health (ICNAS) is a translational biomedical research 
effort that ranges from new molecular probes to human imaging  
of brain structure, chemistry and function.  
W
e feature a fully translational biomedical 
 research effort, from the design of new molec-
ular probes to human imaging of brain struc-
ture, chemistry and function with a focus on the human 
brain (Medical Imaging Branch of Euro-BioImaging). 
 ICNAS started in 2008 and operates a mature imaging 
 infrastructure facility. We have leading expertise, instru-
mentation and cutting-edge imaging facilities.
Together with five universities, we have eight collaborat-
ing research nodes. Several European networks are also 
collaborating with us. Our mission includes developing 
and exploiting new imaging technologies driving devel-
opment and access to state-of-the-art imaging instru-
mentation. Together with CHUC (the University Hospi-
tal of Coimbra) and its Nuclear Medicine Department, 
we also cover advanced research and clinical areas in the 
areas of cardiology and oncology.
We have defined training programs, including short- and 
medium-term courses in advanced neuroimaging meth-
odologies. Initiatives such as the Brain Imaging Network 
are instrumental to help solve the societal challenge of 
obtaining a sustainable healthcare system. We hope to 
 accomplish this by helping establish the use of the most 
updated imaging technologies to provide advanced diag-
nostics in combination with better and more cost- 
efficient treatment.
Our participation in the National Roadmap, approved 
after international evaluation, is justified by the impor-
tance of our National Medical Imaging Infrastructure. In 
fact, the range of our activities covers all the medical 
imaging work packages of Euro-BioImaging, from trans-
lational research using molecular and functional imaging 
techniques to basic and clinical research in neuroscience, 
including clinical trials. 
The level of complementarity is also very high because of 
our specialized radiochemistry unit, which can synthe-
size new compounds for molecular imaging in humans 
and animals, using several tracers, including C11. More-
over, we also have the possibility of developing new mag-
netic resonance imaging (MRI) approaches, taking 
advantage of the research collaboration with Siemens and 
interactions with centers such as John Hopkins Hospital 
and the Martinos Center at Harvard Medical School. Our 
infrastructure has proven its ability to study large cohorts 
of healthy volunteers (more than 600 on a recent study of 
aging of different visual functions) and patients 
(hundreds of patients studied in several national and 
international neuroimaging/phenotyping projects on 
neurodegenerative diseases). This helps us design new 
molecular probes for imaging of structure, chemistry and 
function with a focus on the human brain. We published 
multimodal studies in top basic and clinical neuroscience 
journals, by adding possibilities to unravel molecular 
mechanisms of disease to the development of novel diag-
nostic imaging biomarkers to better define and detect 
early  disease processes and test new therapies.
We have implemented MR- and PET-based imaging 
probes based on dopamine , GABA and glutamate, which 
are neurotransmitters that have been related to develop-
mental, aging, neurological and psychiatric diseases 
affecting cortical- basal ganglia interactions such as 
Parkinson’s Disease and related syndromes including 
Huntington’s disease, schizophrenia and autism. The 
potential was demonstrated by recent publications in 
prestigious journals such as Brain and Neurology that 
confirmed in humans the hypothesis raised in animal 
models of impaired inhibitory neurotransmission. We 
prioritize understanding diseases associated with vision 
and aging and neuropsychiatric disorders associated with 
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National Taiwan University Hospital (NTUH) is known 
for pioneering research on diseases endemic to Taiwan 
and providing a basis for treatment guidelines in 
many clinical disciplines. NTUH plays a leading role in 
clinical trials and research in the Asia-Pacific region. 
N
TUH was founded in 1895. It was initially located 
at Dadaocheng, Taipei, and then was relocated to 
the present site in 1898. The building was initially 
constructed out of timber and then it underwent renova-
tion in 1912 to become a tropical renaissance-style build-
ing. When completed in 1921, it was the largest and most 
modern hospital in Southeast Asia. Currently, the hospi-
tal employs just over 6,000 staff, has approximately 2,400 
beds and serves over 8,000 outpatients daily. Each year, 
approximately 2,075 clinical interns and medical stu-
dents, 1,010 residents, and 790 other healthcare workers 
receive clinical training at NTUH. NTUH is also commit-
ted to promoting international collaboration, thereby 
gaining experience and knowledge from the medical 
development of advanced countries, and thus enhancing 
the delivery of high-quality medical care in Taiwan.
PROVIDING HIGH-QUALITY AND PATIENT- 
CENTERED CARE  
For more than a hundred years, NTUH has been provid-
ing the people of Taiwan with high-quality and compas-
sionate medical services. The success of NTUH medical 
care services lies in the prompt and effective introduction 
of the latest medical knowledge to and prevent disease 
and improve the care of patients. NTUH continues to 
uphold its philosophy of “patient-centered” medical 
services to provide medical care at the highest level. The 
objective is not only that these efforts will enable NTUH 
to set an example of medical care in Taiwan, but also in 
Southeast Asia and other developing countries.
NTUH is committed to the promotion of international 
cooperation. NTUH runs myriad exchange programs 
with top international academic medical centers to facili-
tate access to the latest knowledge and information on 
medical treatments in order to improve medical research 
and continuing medical education, and advance the qual-
ity of medical care in Taiwan. In accordance with the 
principles of equality and mutual benefit, there are a 
number of ongoing international cooperative training 
programs, including programs for medical students, 
attending physicians, and other medical professionals. 
There are active collaborative programs with institutions 
in France, Japan, Korea and Estonia.
MEDICAL RESEARCH AS ONE OF NTUH’S  
CORE VALUES
As a university hospital and medical center, NTUH has 
identified medical research as one of its core missions 
because it not only affects competitiveness, but also has a 
far-reaching impact on the nation's healthcare technolo-






essence of medical research is innovation and the fruit of 
research and development is the direct result of the unre-
lenting dedication of each staff to meet “patients’ medical 
needs.” NTUH’s focus on “medical research” has enabled 
it to carry out clinical breakthroughs in the world and 
Asia. NTUH has enjoyed a reputation for world-class 
pioneering achievements in hepatitis research, organ 
transplantation, cancer diagnosis and treatment, biopho-
tonics, tissue materials, emergency and critical care, im-
munology, cardiology, infertility, dermatology, ophthal-
mology, orthopedics and minimally invasive surgeries.
In order to pursue high-quality research and conform to 
international research ethics standards, NTUH pro- 
actively participates in the Association for the Accredita-
tion of Human Research Protection Program. The phar-
macogenomics laboratory received accreditations from 
the Taiwan Accreditation Foundation and the College of 
American Pathologists. More than 200 clinical trials are 
initiated at NTUH each year, many of them part of global 
multinational trials. There are more than 40 ongoing new 
drug Phase I trials at NTUH.
INNOVATIVE RESEARCH ACHIEVEMENTS 
IN THE PAST 5 YEARS
1. Investigators at the Department of Medical 
Research of NTUH and the Department of 
Chemical Engineering of National Tsing Hua 
University collaborated to work on the latest 
Enterovirus (EV) vaccines. Using molecular 
biology techniques, the joint team researched and 
developed a virus-like particle (VLP) vaccine. 
Animal trials of this VLP vaccine on macaque 
monkeys were successfully completed. The 
results showed the animals developed substantial 
concentration of antibodies, as well as the ability 
to neutralize EV-71. This research finding was 
published in the journal Vaccine. This research 
team is the international frontrunner in the rese-
arch and development of EV vaccines.
2. A multi-center randomized trial led by the 
investigators from the Department of Internal 
Medicine of NTUH confirmed the efficacy of a 
novel sequential treatment as the first-line 
treatment for Helicobacter pylori infection –  
a common pathogen for gastric diseases. In this 
research, the research team extensively analyzed 
antibiotic resistance, designed a decision  
model that could predict the efficacy of anti-H. 
pylori treatment in different regions around the 
world, and disseminated an important message 
that the optimal regimen should be tailored 
to the local prevalence rate of the antibiotic 
resistant strains. Results of the study were pub-
lished in one of the top medical journals,  
The Lancet, in 2013.
3. The pneumothorax research team conducted a 
randomized clinical trial to verify that the addi- 
tion of minocycline pleurodesis after the standard 
treatment of aspiration and drainage for primary 
spontaneous pneumothorax can effectively re-
duce the rate of recurrence and the probability of 
a follow-up operation. The study was published 
in The Lancet in 2013. 
4. Through a collaborative team effort, researchers 
from National Taiwan University Hospital 
(Department of Internal Medicine and Depart-
ment of Medical Genetics), National Taiwan 
University College of Medicine and Academia 
Sinica discovered the genes that cause antithyroid 
drug-induced agranulocytosis. Results of this re-
search were published in Nature Communications 
in 2015.  
Author
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with individual risk or with a specific prognosis. Even 
brain images can be used as biomarkers as recent exam-
ples from psychiatric research shows. Recognizing and 
diagnosing mental illness has always been a particular 
challenge for psychiatrists and researchers alike. How-
ever, recently, functional magnetic resonance imaging 
or functional MRI (fMRI), which is a neuroimaging 
procedure, has been used to measure blood flow and 
thereby neuronal activity. A recent report showed that 
fMRI markers could identify autistic patients with good 
accuracy. This is most certainly a major advance in the 
diagnosis of mental illnesses. 
USING IMMUNE CELLS TO TREAT CANCER
Harnessing the body’s own immune system against can-
cer cells has long been on the mind of oncologists and 
cancer researchers. This idea stems from old but largely 
anecdotal observations that cancer patients suffering 
from viral infections sometimes had a more favorable 
outcome than their non-infected counterparts. The con-
cept is plausible, since cytotoxic T-cells that can recognize 
and kill virus-infected cells are part of our immune 
defense and their “killer” capacity could be directed 
against tumor cells. Recently, we have witnessed a come-
back of this idea in the form of a new therapy that uses so 
called chimeric antigen receptor carrying (“CAR”) 
T-cells. Here, T-cells are collected from a cancer patient 
by apheresis and are treated to express a CAR, which is 
nothing else than a modified T-cell receptor able to rec-
ognize a specific tumor antigen expressed on the surface 
of a cancer cell. The CAR-carrying T-cells are then 
expanded in vitro and re-injected into patients, where 
they eliminate the cancer cells that carry the cognate 
antigen. Examples are T-cells with CARs directed against 
the disialoganglioside GD2, which can recognize and kill 
neuroblastoma cells expressing GD2 or T-cells with CARs 
for CD19, which have already shown high potential to kill 
B-cell type leukemia cells. 
NEW GENOME EDITING TOOLS FOR GENE 
THERAPIES AND THE RISK OF “GENE DRIVE”
A new genome editing tool called CRISPR/Cas9 is 
another example of how discoveries from fundamental, 
non-targeted research can provided powerful tools for 
clinical applications. By investigating how bacteria deal 
with foreign DNA, for example coming from bacterio-
phages, researchers have discovered the CRISPR/Cas 
system. The immense significance of this discovery and 
its potential for biomedical research and gene therapy 
was immediately recognized and experiments with these 
new tools are now present in laboratories the world over. 
CRISPR associated, or “Cas”, proteins are RNA-guided 
DNA endonucleases. CRISPR stands for Clustered Regu-
larly Interspaced Short Palindromic Repeats and together 
with the protein Cas9, for instance, enable bacteria to 
degrade foreign DNA at specific sites. When the Cas9 nu-
clease and the right guide RNA molecules are delivered 
into a cell, the genome of this cell can be cut at a precise 
location, exactly where the guide RNA finds a 
complementary sequence. This enables the removal or 
destruction of genes, corrections of mutations or the 
introduction of new mutations in any given genome. This 
opens infinite possibilities to design new therapies in par-
ticular for monogenetic diseases, but also for infectious 
diseases or to revert therapy resistance. CRISPR/Cas 
genomic editing has been tested and already proven capa-
ble of correcting gene defects in mouse models for sickle 
cell anemia, muscular dystrophy and cystic fibrosis; hence 
for diseases where single gene mutations are at the root of 
the problem. Other applications include the targeting of 
viruses (e.g., herpes, hepatitis B or even HIV) where a 
DNA intermediate is required for their life cycle and 
which can be targeted by Cas9 and suitable guide RNAs 
to be eliminated or incapacitated. 
In 2014, researchers from MIT and their colleagues who 
co-discovered the CRISPR/Cas9 system described a way 
to use this editing tool to “drive almost any genome al-
teration through sexually reproducing populations.” 
They declare that “gene drive could benefit human 
health for instance by altering insect populations trans-
mitting diseases such as malaria.” However, the spread-
ing of genome alterations through entire populations 
could have unpredictable consequences and it remains 
to be seen whether the elimination of entire species by 
gene drive – even if it concerns flies transmitting deadly 
diseases – is controllable. Therefore, some of the 
researchers that were involved in the discovery the 
CRISPR/Cas9 system and had demonstrated its poten-
tial to manipulate entire genomes have called for a 
moratorium on using CRISPR/Cas9 on the human germ 
line. This ongoing debate reminds us again that many 
new scientific discoveries and breakthroughs, as excit-
ing as they are, still bear risks that we have to weigh with 
caution against all potential benefits. 
Translational research promises to use the discoveries of fundamental 
biomedical research to develop new clinical applications. Whether  
this promise has been kept is a matter of intense debate. Here we 
demonstrate how both fundamental and applied research play roles in 
the development of new and innovative treatments. 
T
his summer, the US Food and Drug Administra-
tion (FDA) has approved two drugs called Aliro-
cumab and Evolocumab. Both are inhibitors of the 
proprotein convertase subtilisin kexin 9 (PCSK9) and 
have the potential to replace the well-established statins 
as the standard treatment for lowering blood cholesterol 
levels. The approval of PCSK9 inhibitors by the FDA is a 
paradigmatic example that fundamental research 
oriented toward a general understanding of biological 
principles can create the knowledge base for the develop-
ment of new drugs. The PSCK9 gene was found during 
research to better understand how proproteins and their 
convertases function. It was quickly recognized that it 
encodes a new proprotein convertase, but its function in 
regulating cholesterol levels was only uncovered when 
PCSK9-deficient mice and humans with crippling PCSK9 
mutations were analyzed and found to have strongly 
reduced cholesterol levels in the blood. It took over 10 
years from the original discovery of PCSK9 to the first 
FDA approval of PCSK9 inhibitors as new drugs. Some 
have even argued that it is questionable whether PCSK9 
would have been found by research directly targeted at 
finding new cholesterol regulating enzymes. 
DISEASES IN THE CROSSHAIRS OF APPLIED 
RESEARCH: THE EXAMPLE OF THE ARTIFICIAL 
PANCREAS 
One of the most fascinating developments in the field of 
applied medical research is the artificial pancreas to treat 
diabetes type 1. The development of the artificial pancre-
as is based on extra-corporal insulin pumps that are used 
today by people with type 1 diabetes. These patients have 
to carefully manage their blood glucose levels to avoid 
hypo- or hyperglycemia. This is particularly difficult at 
night, where periods of hypoglycemia remain the most 
common adverse effect of insulin therapy. The newest 
generation of the artificial pancreas, which should be 
available to patients within the next 2-3 years, use com-
puter algorithms that allow a precise dosing of insulin 
and glucagon in response to varying blood glucose con-
centrations, which are measured using a sensor. The 
monitoring of blood glucose and the activation of the 
insulin or glucagon injections are continuous and will 
ideally be reviewed by the patient via smartphone appli-
cations and should increase the quality of life of diabetes 
type 1 patients significantly.
NEW BIOMARKERS AS “COMPANION  
DIAGNOSTICS” FOR PRECISION MEDICINE  
Biomarkers are now used increasingly in clinical prac-
tice to follow the course of a disease more precisely and 
to select suitable treatments more adequately, for 
instance, according to an individual patient’s genetic 
make-up or to identify therapy responders within entire 
patient cohorts. Biomarkers can be genetic variants, 
metabolites or substances which, once introduced into 
an organism, allow a physician to monitor a specific 
physiological parameter or even the function of whole 
organs. Rubidium chloride, used to evaluate heart mus-
cle perfusion, is one such example. Other biomarkers 
may indicate changes in expression of proteins or 
metabolites that correlate with the course of a disease, 
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lives influence their telomeres. So many conditions in 
people’s lives actually impact on disease risks, but it was 
very hard to accept that your neighborhood is actually a 
risk factor for cardiovascular disease and diabetes. It 
turns out stress makes your telomeres wear down faster.
How do you bottle that knowledge? 
It’s very interesting because it turns out that everything 
your mother told you to do is right, in terms of the effects 
on maintaining telomeres. Every good parent says, “sleep 
well, eat healthily, get some exercise, have a good atti-
tude.” All these things help preserve the ends of our chro-
mosomes, it turns out. You’re not asking for an untested 
drug. It doesn’t cost you anything to walk.
If we emphasize treatments but we don’t emphasize 
prevention, then we’re never going to get anywhere. The bi-
ology of prevention is more complex and less urgent- 
seeming, but in terms of public health overall, it’s simple: 
that’s where we also need to be putting the money. Nobody 
likes this because it’s too distant-seeming and does not have 
the same commercial attractions as disease treatments.
Thus, prevention is a much more challenging ques-
tion, because the incentive is always to treat a disease that 
is there right now. Of course, by that time it’s way too late 
and the disease has already done a lot of damage. With 
telomeres we have a really good molecular biomarker.
That, to me, is very practical. No one could love 
Western medicine more than me, but at some point you 
realize that part of the picture is preventing and intercept-
ing disease. 
In your presentation you gave a great example: People 
who have bladder cancer and simultaneously have both 
shorter telomeres and depression at the time of diagnosis 
of their cancer are far more likely to die than people with 
just one of those conditions – also that people with de-
pression have shorter telomeres. What’s the link? 
Depression has big physiological readouts and clear 
increases in risks for co-morbid diseases like cardiovascu-
lar and diabetes. It clearly causes a big physiological change. 
If someone who is depressed has cancer, the host – the 
body –  in which the cancer is growing is not the same as a 
non-depressed host. 
And there is a clear dose dependency between telo-
mere shortness and depression history and severity. 
“ You make 
the biggest 
impact by 
doing  basic 
research”
Elizabeth Blackburn is president of the Salk Institute for Biological Studies,  
one of the world’s preeminent research centers. In 2009, Blackburn won  
the Nobel Prize in Medicine for discovering telomeres, which serve as protective  
caps on chromosomes and are essential for preserving genetic information.  
Telomeres seem to play a key role in aging and diseases such as cancer, and  
Blackburn’s work helped jumpstart new research in these areas.
Congratulations on your recent appointment to head the 
Salk Institute. Are you here to advocate on behalf of the 
translational potential for basic research?
Blackburn — I think I’m more here to cheer for health. To 
me that is the overarching consideration. Jonas Salk in-
vented a vaccine for polio in the 1950s. And he didn’t get 
rich from it, but he had this vision: You make the biggest 
impact by doing basic research.
Despite all our knowledge, there is still such a lot that 
we don’t understand about how diseases unfold, especially 
the non-infectious ones. Those diseases are not really well 
understood. Alzheimer’s is a really dramatic example.
Please tell us about your experience researching the telo-
mere – did you think it would have clinical applications? 
It began as very basic research – what’s at the end of chro-
mosomes? Nobody knew. I was using whatever molecular 
techniques were available to get an answer.
It turned out that telomeres had inherent properties 
that could mean chromosomes would become unpro- 
tected over time. What has been exciting over the years 
has been finding out how that actually plays out in human 
lives. Of course, we have life expectancies in developed 
countries of 80 years or more, so in humans you have to 
ask questions in ways that you can’t ask in rapid, short life 
model organisms.
Non-communicable diseases are basically when the 
complex machine of the human body starts breaking 
down. They are truly huge killers – diabetes, cancers, car-
diovascular diseases, strokes, even lung disease. And then 
neurodegenerative disease is having such an impact, not 
so much by killing people but by having a real impact on 
quality of life. When telomeres shorten too much over de-
cades of life, that starts to accelerate these diseases and 
make them worse. 
How did you make that transition from looking at 
telomeres in the model organisms to humans? 
I went to a medical school and somebody says to me, oh, 
would you like to join our cancer investigation. By then 
people knew the enzyme we’d discovered played a role in 
most human cancers.
Then a young colleague, Elissa Epel (Department of 
Psychiatry, University of California) came in one day and 
said, “When human beings are stressed, then they look 
more and more aged, what happens to their telomeres?” 
That grew a whole field looking at what things in people’s 
“ It turns out that 
everything your mother 
told you to do is right,  
in terms of the effects on 
maintaining telomeres.”
When you look at telomeres in a number of cohorts, the 
more days of lifetime accumulated untreated depression a 
person has in their past the shorter their telomeres. If you 
could measure telomere length in long-term depressed 
individuals, you might be able to assess their risk of 
co-morbidities. 
Is there a way to systematize the dialogue between clini-
cians and basic scientists? 
That can be done at a sort of policy or strategic level from 
the national funding agency. In my experience, the Na-
tional Institutes of Health in the US showed a real willing-
ness to see the value in why this kind of research should 
be funded. That’s been one thing I’ve observed that has 
really changed in the last decade, in a good way.
You mean encouraging as many different disciplinary ap-
proaches as possible in a grant?
If you’re going to write a good proposal to do good 
research on complex problems – and human biology is 
complex! – you’re going to need to talk to people who 
have very different training, a very different mindset, and 
different languages that they use.
I think it works more when there are really material 
incentives. In my case it was grants. I did it within, by and 
large, a big research university. But then I felt it was really 
very easy to do between research universities as well. You 
need the right sort of openness, which is to say to one’s 
basic scientists that your clinical colleagues are actually 
really smart, but in ways that are different from your 
smartness. I found you need to talk one-on-one because 
you really need to make sure you’re talking about the 
same things.
So it’s a matter of changing the funding and the culture? 
I have been a basic scientist for decades, and it wasn’t that 
hard to start conversations. But you have to think that 
there was some value to it. 
If you could come up with a pill to preserve telomerase, 
would I want to take it? 
You’d be stupid because significant research in humans 
indicates that you’d increase your risks of some cancers. 
Because my cells would never die? 
Increases in telomere maintenance is associated with 
increased risks for some cancers. When you’re looking at 
things over decades and decades of life, small effects can 
cumulatively add up to big overall cumulative risks from 
cancer – imagine the risk goes up a few percent each year, 
but that plays out for three decades. That’s going to have a 
big overall risk effect.
We already have ways that we know are better at 
maintaining telomeres – exercise, rest and reducing 
stress, for instance. They are free, so those are the smart 
things to go with.  
INTERVIEW
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Translational research is advancing innovation, making it even more attractive 
for further investment and development. A central aspect of this process is  
the effective translation of knowledge, mechanisms and techniques generated by  
advances in fundamental scientific research, turning them into novel 
approaches for prevention, diagnosis and treatment.
GLOBAL FUNDING FIGHTING AIDS
STATEMENT
It’s very important 
for decision-makers 
to incentivize this  
kind of work. This  
is where we will see  
the next step up to 
unlocking the  
potential of value- 
based healthcare. 
Diseases mostly found in low-income and 
middle-income countries like malaria  
and tuberculosis receive just 1% of all global 
funding for health research, despite 
WHO estimates that these diseases account 
for more than 12.5% of the global disease  
burden.
Since the disease's peak in 
2005, AIDS-related deaths 
have dropped: In 2015, 1.1  
million people around the 
world died from AIDS-related 
causes, a 45% drop from the  





(National Center for Advancing  
Translational Sciences, 2013)
Worldwide, the rate fell by more than 
half from 1990 to 2015, and deaths  
of children under 5 fell from 12.7 million  
to 6 million, having dropped from  
90 to 43 deaths per 1,000 live births.
CHILD MORTALITY
(United Nations Development Programme, 2016)
1 IN 10,000 scientific 





71.4 Years in 2015. 
69.8 Years in 2010. 
68.0 Years in 2005. 





On average, it costs  
US$ 2.6 billion  
to develop and gain  
marketing approval  
for a new drug.
(Tufts Center for the Study of  
Drug Development, 2014)
Christina Akerman (President 
International Consortium for 
Health Outcomes measurement) 
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OCT 15-17, 2017 INNOVATION FOR LIFE
HOPE IS WHAT ENERGIZES OUR RESEARCHERS TO PUSH 
THE FRONTIERS OF MEDICAL INNOVATION EVERY DAY. 
To fi ght against dengue fever, hypercholesterolemia, 
diabetes and atopic dermatitis, our researchers help 
turn discoveries into solutions -- even faster. With major 
treatment launches planned by 2018, Sanofi  shares the 
hopes of millions of patients and public health partners. 
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